



GASKELL

Bereavement Information Pack

For those bereaved
through suicide or other
sudden death

*Kate Hill, Keith Hawton,
Aslög Malmberg and Sue Simkin*

It is often difficult for relatives and friends of people who die by suicide or other sudden death to get help. This pack is specifically designed for such people. It highlights the areas of greatest difficulty for the bereaved person and offers advice on how to get support from friends and family and bereavement support and counselling organisations, as well as providing a list of recommended reading. A substantial number of bereaved individuals have already found it helpful. This pack is fully supported by The Samaritans and The Royal College of Psychiatrists.

● £5.00 ● 1997 ● ISBN 1 901242 08 0

Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from Book Sales, Publications Department, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG (Tel. +44(0)171 235 2351, extension 146). The latest information on College publications is available on the INTERNET at: www.rcpsych.ac.uk

Epilim Oral Prescribing Information

Presentation Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in severe cases provided that plasma levels are monitored; above 40mg/kg/day chemistry and haematology should be monitored. Epilim Chrono may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** **Contraindications** Active liver disease, family history of severe liver disease, porphyria, hypersensitivity to valproate. **Side effects** Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia, pancytopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, hearing loss, vasculitis, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine and erythromycin may inhibit the metabolism of Epilim. Mefloquine may decrease serum valproate levels. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1-2% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation:** January 1997.

References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; 57: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; 7: 219-225.



Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.

Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,¹ it is well tolerated (particularly with regard to cognitive function)², and offers patients the convenience of once-daily dosing.

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.

DEC 17 1997

PROPERTY OF
MEDICAL LIBRARY
ST. BARNABAS HOSPITAL
103rd St. & 3rd Ave
BRONX, N.Y. 10457



Epilim[®] CHRONO[®]
Sodium Valproate Ph. Eur.
Valproic Acid Fr.P
Controlled Release

Once-daily management
for all forms of epilepsy

Prescription
97% of psych



Fast Response

Can start to improve symptoms within seven days

DEC 17 1997



FIRST CHOICE

LUSTRAL 50mg
sertraline

PROPERTY OF
MEDICAL LIBRARY
EL DARRAGAS HOSPITAL
1103rd St. & 3rd Ave
NEW YORK, N.Y. 10457

A first choice antidepressant



Abbreviated Prescribing Information: Lustral (sertraline)
Presentation: Tablets containing 50mg or 100mg sertraline. **Indications:** Treatment of symptoms of depressive illness, including accompanying symptoms of anxiety. Prevention of relapse or recurrence of depressive episodes, including accompanying symptoms of anxiety. **Dosage:** Lustral should be given as a single daily dose. The initial dose is 50mg and the usual therapeutic dose is 50mg daily. Dosage can be further increased, if

appropriate, to a maximum of 200mg daily. Patients should be maintained on the lowest effective dose and doses of 150mg or more should not be used for periods exceeding 8 weeks. **Use in children:** Not recommended. **Use in the elderly:** Usual adult dose. **Contraindications:** Hypersensitivity to Lustral. Hepatic insufficiency. Do not use with, or within two weeks of ending treatment with, MAOIs. At least 14 days should elapse before starting any MAOI following discontinuation of Lustral. **Use during pregnancy:** Lustral should be used only if clearly needed. **Lactation:** Not recommended. **Precautions, warnings:** Renal insufficiency, unstable epilepsy, ECT, driving. Lustral should be discontinued in a patient who develops seizures. Lustral should not be administered to patients concurrently being treated with tranquillizers who drive or operate machinery. Patients should be closely supervised for the possibility of suicide attempt or activation of mania/hypomania. **Drug Interactions:** Caution with other centrally active medication. Serotonergic drugs including tryptophan, sumatriptan and fenfluramine should not be used with Lustral. Lithium levels should be monitored. Although Lustral has been shown to have no adverse interaction with alcohol, concomitant use with alcohol is not recommended. Interactions with other highly protein bound drugs should be borne in mind. The potential of Lustral to interact with e.g. warfarin, diazepam, tolbutamide and cimetidine have not been fully assessed. With warfarin prothrombin time should be monitored when

Lustral is initiated or stopped. **Side-Effects:** Dry mouth, nausea, diarrhoea/loose stools, ejaculatory delay, tremor, increased sweating, dyspepsia, dizziness, insomnia and somnolence. Rarely, abnormal LFTs, hyponatraemia. Malaise and rash have been reported. Seizures (see precautions, warnings). The following have been reported with Lustral but may have no causal relationship: movement disorders, menstrual irregularities, hyperprolactinaemia and galactorrhoea. As with all psychoactive medicines, possible side effects on discontinuation. **Legal Category:** POM. **Basic NHS Cost:** 50mg tablet (PL57/0308) Calendar pack of 28, £26.51; 100mg tablet (PL 57/0309) Calendar pack of 28, £39.77. Further information on request. Invicta™ Pharmaceuticals or Richborough™ Pharmaceuticals Divisions of Pfizer Limited, Sandwich, Kent. Date of preparation: June 1997

66972 June 97



The British Journal of Psychiatry

INDEX TO VOLUME 171



JULY–DECEMBER
1997

© The Royal College of Psychiatrists

ISSN 0007-1250

Index to Volume 171

Compiled by Linda English

PART I — SUBJECTS	3–16
PART II — CONTRIBUTORS	16–23
PART III — BOOK REVIEWS	23–24

Abbreviation: C, correspondence

PART I. SUBJECTS

- Abnormal Involuntary Movements Scale**
Poor memory, negative symptoms and abnormal movements in never-treated patients with schizophrenia. R. G. McCreadie *et al* 360–363
- Acamprosate**
Efficacy and safety in the treatment of detoxified alcohol-dependent patients. I. Pelc *et al* 73–77
- Admission rates**
Social indicators and prediction of psychiatric admission in different Diagnostic groups. Anthony P. Boardman *et al* 457–462
- Adolescence**
Family functioning and life events in outcome of anorexia nervosa. Clive North *et al* 545–549
Long-term cannabis use and mental health. Wayne Hall & Nadia Solowij (*Editorial*) 107–108
see also Childhood and adolescence
- Affective disorders**
Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
see also Bipolar disorder, Depression, Dysthymia and Mania
- African–Caribbeans**
Increased rate of psychosis in Britain is not due to an excess of pregnancy and birth complications. G. Hutchinson *et al* 145–147
- Ageing**
Eugeria, longevity and normal ageing. Karen Ritchie (*Editorial*) 501
- Agranulocytosis**
Eosinophilia, and clozapine. P. Bailey (C) 90. M. D. Adityanjee *et al* (C) 485–486
- Alcohol misuse**
Comorbidity of mental disorders with substance misuse. Wayne Hall & Michael Farrell (*Editorial*) 4–5
- Francis Keaney *et al* (C) 484–485
Dual diagnosis of severe mental illness and substance misuse: a case for specialist services? Sonia Johnson (*Editorial*) 205–208
Efficacy and safety of acamprosate in the treatment of detoxified patients. I. Pelc *et al* 73–77
Liver transplantation for alcoholic liver disease. Louise Howard & Tom Fahy (*Editorial*) 497–500
Suicide and substance misuse. Jan Neeleman & Michael Farrell (*Editorial*) 303–304
- Alzheimer's disease**
Clinical advances in degenerative dementias. Bruce L. Miller (*Editorial*) 1–3
Dementia with Lewy bodies. Neuropsychological and imaging differences. R. L. Allen *et al* (C) 486–487
Study of depression and anosognosia. Sergio E. Starkstein *et al* 47–52
- Amisulpride**
Low-dose neuroleptics in chronic schizophrenia. J. C. Speller *et al* 564–568
- Analyses**
Excess mortality of schizophrenia. Meta-analysis. Steve Brown (*Review Article*) 502–508
History of violent behaviour and schizophrenia. WHO study. Jan Volavka *et al* 9–14
Large same-year effects: fact or artefact? Edward L. Peterson & Naomi Breslau (C) 487–488.
Ronald C. Kessler (*Author's reply*) (C) 488
Publication trends of papers on schizophrenia. Analysis of three psychiatric journals. Massimo Morlino *et al* 452–456
Social indicators and prediction of psychiatric admission in different diagnostic groups. Anthony P. Boardman *et al* 457–462
- Anorexia nervosa**
Family functioning and life events in the outcome in adolescents. Clive North *et al* 545–549
The overvalued idea. J. Treasure (C) 190
- Anosognosia**
Study of depression and anosognosia in Alzheimer's disease. Sergio E. Starkstein *et al* 47–52
- Antidepressants**
Cognitive therapy and pharmacotherapy in out-patients with recurrent depression. I.-M. Blackburn & R. G. Moore 328–334
Cost-effectiveness of treatment. L. Head and V. O'Keane (C) 88
Suicide and cost-effectiveness. S. Lynch (C) 189
Treatment, outcome and predictors of response in elderly depressed in-patients. G. Pinner & W. P. Bouman (C) 289. T. J. Heeren *et al* (*Authors' reply*) (C) 289–290
see also Selective serotonin reuptake inhibitors and Tricyclics
- Antipsychotics**
Establishing cost-effectiveness. David M. Taylor (C) 486. Clive E. Adams (C) 486
5-HT_{2A} receptor occupancy *in vivo* and response to olanzapine and sertindole. M. J. Travis *et al* (C) 290–291
Subjective quality of life in schizophrenia. M. R. Agarwal (C) 392. M. Franz (*Author's reply*) (C) 392. S. Sengupta & N. Kar (C) 587
see also Neuroleptics and individual names
- Anxiety disorders**
Brain blood flow. J. V. Lucey *et al* 346–350
Costs of community care for older people. Gill Livingston *et al* 56–59
Depression. In asylum-seekers. J. J. Rodenburg *et al* (C) 394

- Depressive disorders. Outcome in primary care. Clare Ronalds *et al* 427–433
- Eye movement desensitisation and reprocessing v. exposure *in vivo* for spider-phobic children. Peter Muris *et al* 82–86
- Maternal stress or anxiety in pregnancy and emotional development of the child. Vivette Glover (*Editorial*) 105–106
- Mental disorders among the community-dwelling elderly in Dublin. Michael Kirby *et al* 369–372
- Arab culture**
- Postpartum psychiatric illness. R. Ghubash & M. T. Abou-Saleh 65–68
- Beck Depression Inventory**
- Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350
- Brief cognitive therapy for major depressive disorder. Christine Scott *et al* 131–134
- Bereitschaftspotentials**
- In schizophrenia. T. Karaman *et al* 31–34
- Bipolar disorder**
- Lithium: balancing risks and benefits. John Cookson (*Evidence-based psychiatry*) 120–124
- Lithium: evidence reconsidered. Joanna Moncrieff (*Evidence-based psychiatry*) 113–119
- Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
- Tests of ‘dissociation’ and mood disorder. H. Merskey (C) 487
- Black ethnic groups**
- Ethnic differences in satisfaction with mental health services. Sue Parkman *et al* 260–264
- Ethnicity and use of acute psychiatric beds. Jonathan Koffman *et al* 238–241
- GP recognition of psychological problems in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541
- Prejudice against providers of psychiatric services. P. Harrison-Read (C) 582
- Prevalence of dementia and depression among elderly people. C. F. M. McCracken *et al* 269–273
- Psychosis and birth complications in African–Caribbeans in Britain. G. Hutchinson *et al* 145–147
- Blood monitoring**
- Clozapine, Chinese and blood. S. A. Chong & L. Chua (C) 89–90
- Bonding disorder**
- ‘Anybody’s child’: severe disorders of mother-to-infant bonding. R. Channi Kumar 175–181
- Disorders of the mother–infant relationship. I. F. Brockington (C) 486
- Borderline Syndrome Index**
- Therapeutic community treatment for severe personality disorder. Bridget Dolan *et al* 274–279
- Bovine spongiform encephalopathy (BSE)**
- Human prion disease. J. G. Longhurst (C) 290
- Brain**
- Bereitschaftspotential in schizophrenia. T. Karaman *et al* 31–34
- Blood flow in anxiety disorders. J. V. Lucey *et al* 346–350
- Grey matter correlates of syndromes in schizophrenia. David E. Rous (C) 484
- 5-HT₂ receptor imaging in major depression: focal changes in orbito-insular cortex. F. Biver *et al* 444–448
- Injury. Psychological consequences of road traffic accidents in children and adolescents. D. Fearnley (C) 393. A. Di Gallo (*Author’s reply*) (C) 393
- Structural neuroimaging in learning disability. Shoumitro Deb (*Review article*) 417–419
- see also Dopamine and 5-Hydroxytryptamine*
- Brazil**
- Multicentric study of psychiatric morbidity. Naomar Almeida-Filho *et al* 524–529
- Brief Psychiatric Rating Scale**
- Randomised controlled trial of cognitive–behavioural therapy for psychosis
- I: Elizabeth Kuipers *et al* 319–327
- II: P. Garety *et al* 420–426
- Sulpiride augmentation in schizophrenia partially responsive to clozapine. R. Shiloh *et al* 569–573
- Britain**
- A very British kind of social psychiatry. Leon Eisenberg (*Review Article, Michael Shepherd Memorial Symposium*) 309–313
- Increased rate of psychosis among African–Caribbeans is not due to an excess of pregnancy and birth complications. G. Hutchinson *et al* 145–147
- see also East Anglia, Edinburgh, London, North Cheshire, Nottingham, Oxford and Royal Lunatic Asylum, Montrose*
- Burn victims**
- Psychological debriefing. Jonathan I. Bisson *et al* 78–81. G. Turnbull *et al* (C) 582. J. I. Bisson & P. L. Jenkins (*Authors’ reply*) (C) 583. R. P. Kraus (C) 583. David Reiss & Morven Leese (C) 583–584
- Camberwell Family Interview**
- Expressed emotion and depression. H. Hayhurst *et al* 439–443
- Cannabis**
- Long-term use and mental health. Wayne Hall & Nadia Solowij (*Editorial*) 107–108
- Schizophrenia. J. G. Longhurst (C) 584. W. Hall (*Author’s reply*) (C) 584–585
- Childhood**
- Eye movement desensitisation and reprocessing v. exposure *in vivo* for spider phobia. Peter Muris *et al* 82–86
- see also Infancy*
- Childhood and adolescence**
- Psychological consequences of road traffic accidents. D. Fearnley (C) 393. A. Di Gallo (*Author’s reply*) (C) 393
- Weight and shape concerns in girls. Peter J. Cooper & Ian Goodyer 542–544
- see also Adolescence*
- Chinese**
- Clozapine and blood. S. A. Chong & L. Chua (C) 89–90
- Tardive dyskinesia and CYP2D6 polymorphism. S.-A. Chong (C) 586
- Chronic fatigue syndrome**
- Cognitive deficits in CFS, acute infective illness or depression. Ute Vollmer-Conna *et al* 377–381
- Simon Wessely (*Reading about*) 92–93. R. Sykes (C) 393
- Citalopram**
- Induced decreased libido. A. Michael & J. J. Herrod (C) 90
- Clapham rail accident**
- PTSD symptoms. Carolyn Selley *et al* 478–482
- Clinical Anxiety Scale**
- Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433
- Clozapine**
- Chinese and blood. S. A. Chong & L. Chua (C) 89–90
- Cost-effectiveness. UK clinic-based study. Katherine J. Aitchison & Robert W. Kerwin 125–130. R. W. Kerwin & K. J. Aitchison (C) 584
- Eosinophilia and agranulocytosis. P. Bailey (C) 90. M. D. Adityanjee *et al* (C) 485–486

- Establishing cost-effectiveness of atypical neuroleptics. Glenn Robert & Peter Kennedy (*Editorial*) 103–104
- Induced hypersalivation. E. Szabadi (C) 89
- Monotherapy and ketoacidosis. M. Pierides (C) 90–91
- Pharmacokinetic interactions. David Taylor (*Review Article*) 109–112
- Sulpiride augmentation in schizophrenia partially responsive to clozapine. R. Shiloh *et al* 569–573
- Cochrane Library**
Establishing cost-effectiveness of antipsychotics. Clive E. Adams (C) 486
- Cognitive-behavioural therapy**
London–East Anglia randomised controlled trial for psychosis
I: Effects of treatment phase. Elizabeth Kuipers *et al* 319–327
II: Predictors of outcome. P. Garety *et al* 420–426
- Cognitive impairment**
Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451
- Cognitive function and fall-related fractures. M. Jelicic & G. I. J. M. Kempen (C) 88–89
- Deficits in chronic fatigue syndrome, acute infective illness or depression. Ute Vollmer-Conna *et al* 377–381
- Executive dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles. Paul J. Scully *et al* 154–158
- Long-term cannabis use and mental health. Wayne Hall & Nadia Solowij (*Editorial*) 107–108
- Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia. R. G. McCreadie *et al* 360–363
- Subjective memory complaints in the elderly: depressive symptoms and future dementia. Ben Schmand *et al* 373–376
- see also* **Dementia**
- Cognitive therapy**
Brief therapy for major depressive disorder in primary care. Christine Scott *et al* 131–134
- Pharmacotherapy. Controlled trial in out-patients with recurrent depression. I.-M. Blackburn & R. G. Moore 328–334
- Common mental disorders**
In primary care in Harare, Zimbabwe. V. Patel *et al* 60–64
- Community care**
Costs for older people. Gill Livingston *et al* 56–59
- Comorbidity**
Clinical trials: severe mental illness and substance misuse. R. Laugharne (C) 587
- Dual diagnosis of severe mental illness and substance misuse: a case for specialist services? Sonia Johnson (*Editorial*) 205–208
- Large same-year effects: fact or artefact? Edward L. Peterson & Naomi Breslau (C) 487–488. Ronald C. Kessler (*Author's reply*) (C) 488
- Mental disorders among the community-dwelling elderly in Dublin. Michael Kirby *et al* 369–372
- Mental disorders with substance misuse. Wayne Hall & Michael Farrell (*Editorial*) 4–5. Francis Keaney *et al* (C) 484–485. I. H. A. Franken & V. M. Hendriks (C) 485
- Remission of transsexualism after comorbid OCD improved with self-exposure therapy. Isaac M. Marks & David Mataix-Cols 389–390
- Consultation-liaison**
Psychiatry and medicine. Richard A. Mayou (*Editorial*) 203–204
- Context of Illness Experience Interview**
Subjective experience of schizophrenia and depression. Janis Hunter Jenkins 20–25
- Coping theory**
Appraisal, psychological adjustment and EE in relatives of patients suffering from schizophrenia. Christine Barrowclough & Michael Parle 26–30
- Corrigenda** 190, 588
- Costs**
Community care for older people. Gill Livingston *et al* 56–59
- Cost-effectiveness of antidepressant treatment. L. Head & V. O'Keane (C) 88
- Cost-effectiveness of clozapine. UK clinic-based study. Katherine J. Aitchison & Robert W. Kerwin 125–130. R. W. Kerwin & K. J. Aitchison (C) 584
- Establishing cost-effectiveness of antipsychotics. David M. Taylor (C) 486. Clive E. Adams (C) 486
- Establishing cost-effectiveness of atypical neuroleptics. Glenn Robert & Peter Kennedy (*Editorial*) 103–104
- Health economics. Paul McCrone & Graham Thornicroft (*Reading about*) 191–193
- Schizophrenia. Martin Knapp (*Review Article*) 509–518
- Service provision for people with schizophrenia. I. Clinical and economic perspective. Fiona H. Lang *et al* 159–164
- Suicide and cost-effectiveness of antidepressants. S. Lynch (C) 189
- Treating out-patients with schizophrenia in Nigeria. Toyin G. Suleiman *et al* 364–368
- Crime**
Violence, and schizophrenia. P. Noble (C) 189–190
- Cultures**
Clozapine, Chinese and blood. S. A. Chong & L. Chua (C) 89–90
- Common mental disorders in primary care in Harare, Zimbabwe. V. Patel *et al* 60–64
- History of violent behaviour and schizophrenia. Jan Volavka *et al* 9–14
- Postpartum psychiatric illness in Arab culture. R. Ghubash & M. T. Abou-Saleh 65–68
- Social course of schizophrenia. A. Cohen & S. Lee (C) 287. T. Craig *et al* (*Authors' reply*) (C) 288
- Subjective experience of schizophrenia and depression among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25
- Cytochrome p450 system**
Pharmacokinetic interactions involving clozapine. David Taylor (*Review Article*) 109–112
- Tardive dyskinesia and CYP2D6 polymorphism in Chinese. S.-A. Chong (C) 586
- Databases**
Sigmund: European database of mental health surveys. C. Polge (C) 91
- Deliberate self-harm**
Cost-effectiveness of antidepressant treatment. L. Head & V. O'Keane (C) 88
- Trends in Oxford, 1985 to 1995. Keith Hawton *et al* 556–560
- see also* **Suicide**
- Delusions**
Depressive delusions and the general election. G. Yorston (C) 585
- Randomised controlled trial of cognitive-behavioural therapy for psychosis, II. P. Garety *et al* 420–426
- Dementia**
Age-related cognitive decline and vision impairment affecting detection. Friedel M. Reischies & Bernhard Geiselmann 449–451
- Costs of community care for older people. Gill Livingston *et al* 56–59
- Degenerative. Clinical advances. Bruce L. Miller (*Editorial*) 1–3
- Depression and anosognosia in Alzheimer's disease. Sergio E. Starkstein *et al* 47–52

- Depression. Prevalence among elderly people in ethnic minorities. C. F. M. McCracken *et al* 269–273
- Mental disorders among the community-dwelling elderly in Dublin. Michael Kirby *et al* 369–372
- Subjective memory complaints in the elderly: depressive symptoms and future dementia. Ben Schmand *et al* 373–376
- With Lewy bodies and Alzheimer's disease. Neuropsychological and imaging differences. R. L. Allen *et al* (C) 486–487
- Depression**
- Aetiology**
- Adverse social circumstances in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438
- Comorbidity**
- Large same-year effects: fact or artefact? Edward L. Peterson & Naomi Breslau (C) 487–488. Ronald C. Kessler (*Author's reply*) (C) 488
- Complications**
- Study of depression and anosognosia in Alzheimer's disease. Sergio E. Starkstein *et al* 47–52
- Subjective memory complaints in the elderly: depressive symptoms and future dementia. Ben Schmand *et al* 373–376
- Course**
- Expressed emotion. H. Hayhurst *et al* 439–443
- Epidemiology**
- Anxiety and depression in asylum-seekers. J. J. Rodenburg *et al* (C) 394
- Mental disorders among the community-dwelling elderly in Dublin. Michael Kirby *et al* 369–372
- Prevalence among elderly people in ethnic minorities. C. F. M. McCracken *et al* 269–273
- Genetics**
- Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
- Outcome**
- In primary care. Clare Ronalds *et al* 427–433
- Treatment, outcome and predictors of response in elderly in-patients. G. Pinner & W. P. Bouman (C) 289. T. J. Heeren *et al* (*Authors' reply*) (C) 289–290
- Pathophysiology**
- 5-HT₂ receptor imaging in major depression: focal changes in orbito-insular cortex. F. Biver *et al* 444–448
- Psychology**
- Cognitive deficits in chronic fatigue syndrome, acute infective illness or depression. Ute Vollmer-Conna *et al* 377–381
- Delusions and the general election. G. Yorston (C) 585
- Expressed emotion. H. Hayhurst *et al* 439–443
- Subjective experience among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25
- Therapy**
- Brief cognitive therapy for major depressive disorder in primary care. Christine Scott *et al* 131–134
- Cognitive therapy and pharmacotherapy in out-patients with recurrent depression. I.-M. Blackburn & R. G. Moore 328–334
- Costs of community care for older people. Gill Livingston *et al* 56–59
- Lithium: evidence reconsidered. Joanna Moncrieff (*Evidence-based psychiatry*) 113–119. M. Bernadt & G. Stein (C) 484
- Outcome, and predictors of response in elderly in-patients. G. Pinner & W. P. Bouman (C) 289. T. J. Heeren *et al* (*Authors' reply*) (C) 289–290
- Plasma noradrenaline response to ECT. C. B. Kelly & S. J. Cooper 182–186
- see also* Antidepressants and Puerperium
- Detoxification**
- Two new methods of rapid intravenous detoxification in heroin addicts. Albert Seoane *et al* 340–345
- Type of hospital setting and treatment outcome with heroin addicts. John Strang *et al* 335–339
- Developing countries**
- Brazilian multicentric study of psychiatric morbidity. Naomar Almeida-Filho *et al* 524–529
- Effects of level of socio-economic development on course of non-affective psychosis. Vijoy K. Varma *et al* 256–259
- Financial cost of treating out-patients with schizophrenia in Nigeria. Toyin G. Suleiman *et al* 364–368
- History of violent behaviour and schizophrenia. Jan Volavka *et al* 9–14
- Social course of schizophrenia. A. Cohen & S. Lee (C) 287. T. Craig *et al* (*Authors' reply*) (C) 288
- Diagnoses**
- Disability, outcome and case-mix in acute in-patient units. Brendon Boot *et al* 242–246
- Dual diagnosis of severe mental illness and substance misuse. Sonia Johnson (*Editorial*) 205–208
- Psychopathological syndromes and familial morbid risk of psychosis. A. Ryan (C) 289. J. Van Os *et al* (*Authors' reply*) (C) 289
- Social indicators and prediction of psychiatric admission in different diagnostic groups. Anthony P. Boardman *et al* 457–462
- Tests of 'dissociation' and mood disorder. H. Merskey (C) 487
- Disasters**
- PTSD symptoms and the Clapham rail accident. Carolyn Selley *et al* 478–482
- Dissociative disorder**
- Tests of 'dissociation' and mood disorder. H. Merskey (C) 487
- Dopamine**
- Altered dopaminergic function and negative symptoms in schizophrenia. M. B. Knable *et al* 574–577
- Dress styles**
- Psychiatrists and their patients: views on forms of dress and address. Julia A. Gledhill *et al* 228–232
- Drivers**
- Suicides. Annakatri Ohberg *et al* 468–472
- Drug misuse**
- Cannabis and schizophrenia. J. G. Longhurst (C) 584. W. Hall (*Author's reply*) (C) 584–585
- Clinical trials: severe mental illness and substance misuse. R. Laugharne (C) 587
- Comorbidity of mental disorders with substance misuse. Wayne Hall & Michael Farrell (*Editorial*) 4–5. Francis Keaney *et al* (C) 484–485. I. H. A. Franken & V. M. Hendriks (C) 485
- Dual diagnosis of severe mental illness and substance misuse: a case for specialist services? Sonia Johnson (*Editorial*) 205–208
- Long-term cannabis use and mental health. Wayne Hall & Nadia Solowij (*Editorial*) 107–108
- Suicide and substance misuse. Jan Neeleman & Michael Farrell (*Editorial*) 303–304
- Two new methods of rapid intravenous detoxification in heroin addicts. Albert Seoane *et al* 340–345
- Type of hospital setting and treatment outcome with heroin addicts. John Strang *et al* 335–339
- see also* Alcohol misuse
- Drugs**
- Comorbidity of mental disorders with substance misuse. Francis Keaney *et al* (C) 484–485

- Pharmacokinetic interactions involving clozapine. David Taylor (*Review Article*) 109–112
- Use of seclusion, restraint, and emergency medication. H. Sequeira & S. Halstead (C) 288–289
- see also **Acamprosate, Amisulpride, Antidepressants, Antipsychotics, Cannabis, Citalopram, Clozapine, d-Fenfluramine, Haloperidol, Heroin, Lithium, Neuroleptics, Olanzapine, Paracetamol, Paroxetine, Risperidone, Selective serotonin reuptake inhibitors, Sertindole, Sulpiride and Tricyclics**
- DSM-III**
Brazilian multicentric study of psychiatric morbidity. Naomar Almeida-Filho *et al* 524–529
- DSM-III-R**
Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451
- Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350
- Eye movement desensitisation and reprocessing v. exposure *in vivo* for spider-phobic children. Peter Muris *et al* 82–86
- Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433
- Plasma noradrenaline response to ECT in depressive illness. C. B. Kelly & S. J. Cooper 182–186
- Subjective experience of schizophrenia and depression. Janis Hunter Jenkins 20–25
- DSM-IV**
Exposure and response prevention in OCD. Merran Lindsay *et al* 135–139
- ICSD-90. Insomnia symptoms and sleep dissatisfaction. Maurice M. Ohayon *et al* 382–388
- Late paraphrenia revisited. Robert Howard & Peter Rabins (*Editorial*) 406–408
- Dual diagnosis**
Severe mental illness and substance misuse: a case for specialist services? Sonia Johnson (*Editorial*) 205–208
- Dublin**
Mental disorders among the community-dwelling elderly. Michael Kirby *et al* 369–372
- Dutch Adult Reading Test**
Subjective memory complaints in the elderly. Ben Schmand *et al* 373–376
- Dyskinesia**
Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia. R. G. McCreadie *et al* 360–363
- Spontaneous dyskinesia in schizophrenic and non-schizophrenic patients. Wayne S. Fenton *et al* 265–268
- see also **Tardive dyskinesia**
- Dysthymia**
Study of depression and anosognosia in Alzheimer's disease. Sergio E. Starkstein *et al* 47–52
- East Anglia**
London. Randomised controlled trial of cognitive-behavioural therapy for psychosis
I: Elizabeth Kuipers *et al* 319–327
II: P. Garety *et al* 420–426
- Eating disorders**
Weight and shape concerns in girls. Peter J. Cooper & Ian Goodyer 542–544
- see also **Anorexia nervosa**
- Economics** see **Costs**
- ECT** see **Electroconvulsive therapy**
- Edinburgh**
Lunacy. Henry Rollin (*One hundred years ago*) 91
- Edinburgh Postnatal Depression Scale**
Postnatal depression and elation among mothers and their partners. A. Lane *et al* 550–555
- Postpartum psychiatric illness in Arab culture. R. Ghubash & M. T. Abou-Saleh 65–68
- Elderly**
Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451
- Cognitive function and fall-related fractures. M. Jelicic & G. I. J. M. Kempen (C) 88–89
- Costs of community care. Gill Livingston *et al* 56–59
- Eugeria, longevity and normal ageing. Karen Ritchie (*Editorial*) 501
- Incidence and risk factors for severe tardive dyskinesia. Michael P. Caligiuri *et al* 148–153
- Late paraphrenia revisited. Robert Howard & Peter Rabins (*Editorial*) 406–408
- Mental disorders among the community-dwelling in Dublin. Michael Kirby *et al* 369–372
- One hundred cases of attempted suicide. Jason Hepple & Catherine Quinton 42–46
- Prevalence of dementia and depression among people in ethnic minorities. C. F. M. McCracken *et al* 269–273
- Seasonal changes in psychological well-being. John M. Eagles *et al* 53–55
- Subjective memory complaints: depressive symptoms and future dementia. Ben Schmand *et al* 373–376
- Treatment, outcome and predictors of response in depressed in-patients. G. Pinner & W. P. Bouman (C) 289. T. J. Heeren *et al* (*Authors' reply*) (C) 289–290
- War pensions. M. Atkins & S. Davies (C) 188–189
- Electroconvulsive therapy**
Plasma noradrenaline response to ECT in depressive illness. C. B. Kelly & S. J. Cooper 182–186
- Emergencies**
Use of seclusion, restraint, and medication. H. Sequeira & S. Halstead (C) 288–289
- Eosinophilia**
Agranulocytosis, and clozapine. M. D. Adityanjee *et al* (C) 485–486
- Agranulocytosis. Clozapine treatment. P. Bailey (C) 90
- Epidemiology**
Ethnicity in psychiatric epidemiology: need for precision. Swaran P. Singh (*Editorial*) 305–308
- Sigmund: a European database of mental health surveys. C. Polge (C) 91
- The evolving face of psychiatric epidemiology. Anthony Mann (*Review Article, Michael Shepherd Memorial Symposium*) 314–318
- see also **under Depression and Schizophrenia**
- Ethics**
Family involvement in the care of people with psychoses. George I. Szmukler and Sidney Bloch (*Editorial*) 401–405
- Ethnicity**
Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438
- Determinants of GP recognition of psychological problems in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541
- Increased rate of psychosis among African-Caribbeans in Britain is not due to an excess of pregnancy and birth complications. G. Hutchinson *et al* 145–147
- In psychiatric epidemiology: need for precision. Swaran P. Singh (*Editorial*) 305–308
- Integration between primary and secondary services in the care of the severely mentally ill: patients' and GPs' views. Jonathan Bindman *et al* 169–174
- Prevalence of dementia and depression among elderly people. C. F. M. McCracken *et al* 269–273

- Subjective experience of schizophrenia and depression among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25
- Suicide by age, ethnic group, coroners' verdicts and country of birth. Jan Neeleman *et al* 463–467
- see also* **Black ethnic groups and Chinese**
- Eugeria**
Longevity and normal ageing. Karen Ritchie (*Editorial*) 501
- Euro-Americans**
Subjective experience of schizophrenia and depression. Janis Hunter Jenkins 20–25
- Europe**
Sigmund: database of mental health surveys. C. Polge (C) 91
- Evidence-based psychiatry**
Closing the gap between research and practice. John R. Geddes & Paul J. Harrison 220–225. Invited commentaries. Ian Anderson *et al* 226–227. J. A. Powell & J. R. Geddes (C) 586–587
- Lithium: balancing risks and benefits. John Cookson 120–124
- Lithium: evidence reconsidered. Joanna Moncrieff 113–119. M. Bernadt & G. Stein (C) 484
- Which evidence to believe? Sudip Sikdar (C) 483–484
- Examinations**
Mini Mental State Examination 373–376, 449–451
- Present State Examination 65–68, 251–255
- Exposure**
Eye movement desensitisation and reprocessing v. exposure *in vivo* for spider-phobic children. Peter Muris *et al* 82–86
- Remission of transsexualism after comorbid OCD improved with self-exposure therapy. Isaac M. Marks & David Mataix-Cols 389–390
- Response prevention. Controlled trial in OCD. Merran Lindsay *et al* 135–139
- Expressed emotion (EE)**
Appraisal, psychological adjustment and EE in relatives of patients suffering from schizophrenia. Christine Barrowclough & Michael Parle 26–30
- Depression. H. Hayhurst *et al* 439–443
- Eye movement desensitisation and reprocessing**
v. exposure *in vivo* for spider-phobic children. Peter Muris *et al* 82–86
- Fall-related fractures**
Cognitive function. M. Jelicic & G. I. J. M. Kempen (C) 88–89
- Families**
Appraisal, psychological adjustment and EE in relatives of patients suffering from schizophrenia. Christine Barrowclough & Michael Parle 26–30
- Expressed emotion and depression. H. Hayhurst *et al* 439–443
- Functioning and life events in outcome of adolescent anorexia nervosa. Clive North *et al* 545–549
- Involvement in the care of people with psychoses. An ethical argument. George I. Szmukler & Sidney Bloch (*Editorial*) 401–405
- Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
- Family planning**
Family planning needs and STD risk behaviours of female psychiatric out-patients. John H. Coverdale *et al* 69–72
- Fathers**
Postnatal depression and elation among mothers and their partners. A. Lane *et al* 550–555
- d-Fenfluramine**
Prolactin responses. Brain 5-HT function in OCD. N. A. Fineberg *et al* 280–282
- Forms of address**
Psychiatrists and their patients: views on forms of dress and address. Julia A. Gledhill *et al* 228–232
- Gender differences**
Age at onset of schizophrenia. L. E. DeLisi (C) 188
- Brazilian multicentric study of psychiatric morbidity. Naomar Almeida-Filho *et al* 524–529
- Executive dysfunction and negative symptoms in schizophrenia: apparent differences in 'static' v. 'progressive' profiles. Paul J. Scully *et al* 154–158
- Minor psychiatric disorder in NHS trust staff. T. D. Wall *et al* 519–523
- General election**
Depressive delusions. G. Yorston (C) 585
- General Health Questionnaire**
GP recognition of psychological problems in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541
- Minor psychiatric disorder in NHS trust staff. T. D. Wall *et al* 519–523
- Relatives of patients suffering from schizophrenia. Christine Barrowclough & Michael Parle 26–30
- Seasonal well-being in the elderly. John M. Eagles *et al* 53–55
- General practice**
Brief cognitive therapy for major depressive disorder in primary care. Christine Scott *et al* 131–134
- Determinants of recognition of psychological problems in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541
- Integration between primary and secondary services in the care of the severely mentally ill: patients' and GPs' views. Jonathan Bindman *et al* 169–174
- Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433
- Service provision for people with schizophrenia. II. Role of the GP. Fiona H. Lang *et al* 165–168. R. J. Simpson (C) 585. F. H. Lang (*Author's reply*) (C) 585–586
- General psychiatry**
In no-man's land. Martin Deahl and Trevor Turner (*Editorial*) 6–8. F. Souza Faria (C) 483
- Genetics**
Opportunities for psychiatry from findings. Michael Rutter & Robert Plomin (*Review Article*) 209–219
- Psychiatry. Michael J. Owen & Peter McGuffin (*Editorial*) 201–202
- Tardive dyskinesia and CYP2D6 polymorphism in Chinese. S.-A. Chong (C) 586
- Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
- Geriatric Mental State (GMS)-AGECAT**
Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451
- Dementia and depression among elderly people in ethnic minorities. C. F. M. McCracken *et al* 269–273
- Mental disorders among the community-dwelling elderly. Michael Kirby *et al* 369–372
- One hundred cases of attempted suicide in the elderly. Jason Hepple & Catherine Quinton 42–46
- Subjective memory complaints in the elderly. Ben Schmand *et al* 373–376
- Girls**
Prevalence and significance of weight and shape concerns. Peter J. Cooper & Ian Goodyer 542–544

Group homes

Clinical and social outcome of stay in small group homes for people with mental illness. Thomas Middelboe 251–255

Haloperidol

Low-dose neuroleptics in chronic schizophrenia. J. C. Speller *et al* 564–568

Hamilton Rating Scale for Depression

Brief cognitive therapy for major depressive disorder. Christine Scott *et al* 131–134

Expressed emotion and depression. H. Hayhurst *et al* 439–443

Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433

Sulpiride augmentation in schizophrenia partially responsive to clozapine. R. Shiloh *et al* 569–573

Head injury

Psychological consequences of road traffic accidents in children and adolescents. D. Fearnley (C) 393. A. Di Gallo (*Author's reply*) (C) 393

Health economics

Paul McCrone & Graham Thornicroft (*Reading about*) 191–193

Health of the Nation Outcome Scales

Disability, outcome and case-mix in acute in-patient units. Brendon Boot *et al* 242–246

Health professionals

Helpfulness of interventions for mental disorders: beliefs compared with the general public. Anthony F. Jorm *et al* 233–237

Minor psychiatric disorder in NHS trust staff. T. D. Wall *et al* 519–523

Heroin

Two new methods of rapid intravenous detoxification in addicts previously treated without success. Albert Seoane *et al* 340–345

Type of hospital setting and treatment outcome with addicts. John Strang *et al* 335–339

Highs Scale

Postnatal depression and elation among mothers and their partners. A. Lane *et al* 550–555

History and Aetiology Schedule

Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451

Hopelessness Scale

Care after attempted suicide. Rob van der Sande *et al* 35–41

Hospitals

Lunacy in London and Edinburgh. Henry Rollin (*One hundred years ago*) 91

Royal Lunatic Asylum, Montrose. Henry Rollin (*One hundred years ago*) 190

Type of setting and treatment outcome with heroin addicts. John Strang *et al* 335–339

see also In-patients

Huntington's disease

Sleep disturbance. N. Taylor & D. Bramble (C) 393

5-Hydroxytryptamine

Brain 5-HT function in OCD.

N. A. Fineberg *et al* 280–282

5-HT₂ receptor imaging in major depression. F. Biver *et al* 444–448

5-HT_{2A} receptor occupancy *in vivo* and response to new antipsychotics. M. J. Travis *et al* (C) 290–291

Hypersalivation

Clozapine-induced. E. Szabadi (C) 89

ICD-9

Driver suicides. Annakatri Ohberg *et al* 468–472

ICD-10

Incidence of schizophrenia in Nottingham. J. Brewin *et al* 140–144

Late paraphrenia revisited. Robert Howard & Peter Rabins (*Editorial*) 406–408

Impact of Events Scale

PTSD symptoms and the Clapham rail accident. Carolyn Selley *et al* 478–482

India

Poor memory, negative symptoms and abnormal movements in never-treated patients with schizophrenia. R. G. McCreddie *et al* 360–363

Infancy

“Anybody’s child”: severe disorders of mother-to-infant bonding.

R. Channi Kumar 175–181

Disorders of the mother–infant relationship. I. F. Brockington (C) 486

Maternal stress or anxiety in pregnancy and emotional development. Vivette Glover (*Editorial*) 105–106

Paroxetine withdrawal syndrome in a neonate. M. L. Dahl *et al* (C) 391–392

Influenza

Schizophrenia. T. J. Crow (C) 91

In-patients

Disability, outcome and case-mix in acute units. Brendon Boot *et al* 242–246

Elderly depressed. Treatment, outcome and predictors of response. G. Pinner & W. P. Bouman (C) 289. T. J. Heeren *et al* (*Authors' reply*) (C) 289–290

Ethnicity and use of acute psychiatric beds. Jonathan Koffman *et al* 238–241

Intensive in-patient and community intervention v. routine care after attempted suicide. Rob van der Sande *et al* 35–41

Low-dose neuroleptics in chronic schizophrenia. J. C. Speller *et al* 564–568

One hundred suicides. France Proulx *et al* 247–250

Suicide among psychiatric in-patients. H. G. Morgan & Ruth Stanton 561–563

Therapeutic community treatment for severe personality disorder. Bridget Dolan *et al* 274–279

see also Hospitals

Insomnia

DSM–IV and ICSD–90 symptoms and sleep dissatisfaction. Maurice M. Ohayon *et al* 382–388

International Classification of Sleep Disorders (ICSD–90)

DSM–IV. Insomnia symptoms and sleep dissatisfaction. Maurice M. Ohayon *et al* 382–388

Interviews

Camberwell Family Interview 439–443
Context of Illness Experience Interview 20–25

Structured Clinical Interview for DSM–III–R Personality Disorders II 283–286

Ketoacidosis

Clozapine monotherapy. M. Pierides (C) 90–91

Late paraphrenia

Revisited. Robert Howard & Peter Rabins (*Editorial*) 406–408

Latinos

Subjective experience of schizophrenia and depression. Janis Hunter Jenkins 20–25

Learning disabilities

Structural neuroimaging. Shoumitro Deb (*Review Article*) 417–419

Use of seclusion, restraint, and emergency medication. H. Sequeira & S. Halstead (C) 288–289

- Leeds Scale for Depression and Anxiety**
Seasonal well-being in the elderly.
John M. Eagles *et al* 53–55
- Leucopenia**
Neutropenia. Risperidone-induced.
Z. Dernovsek and R. Tavcar (C)
393–394
- Lewy body dementia**
Alzheimer's disease.
Neuropsychological and imaging
differences. R. L. Allen *et al* (C)
486–487
Clinical advances in degenerative
dementias. Bruce L. Miller
(Editorial) 1–3
- Life events**
Family functioning and life events in
outcome of adolescent anorexia
nervosa. Clive North *et al* 545–549
- Life Events and Difficulties Schedule**
Adverse social circumstances and
depression in people of Pakistani
origin in UK. Nusrat Husain *et al*
434–438
Outcome of anxiety and depressive
disorders in primary care. Clare
Ronalds *et al* 427–433
- Lithium**
Balancing risks and benefits. John
Cookson (Evidence-based
psychiatry) 120–124
Evidence-based psychiatry: which
evidence to believe? Sudip Sikdar
(C) 483–484
Evidence reconsidered. Joanna
Moncrieff (Evidence-based
psychiatry) 113–119. M. Bernadt
& G. Stein (C) 484
Lethal poisoning with sustained-
release preparations. M. Hrdlicka
& P. Sevcik (C) 586
- Liver transplantation**
For alcoholic liver disease. Louise
Howard & Tom Fahy (Editorial)
497–500
- London**
East Anglia. Randomised controlled
trial of cognitive-behavioural
therapy for psychosis
I: Elizabeth Kuipers *et al* 319–327
II: P. Garety *et al* 420–426
Ethnic differences in satisfaction with
mental health services among
people with psychosis in South
London. Sue Parkman *et al* 260–264
Ethnicity and use of acute psychiatric
eds: survey in North and South
Thames regions. Jonathan Koffman
et al 238–241
Lunacy. Henry Rollin (*One hundred
years ago*) 91
PTSD symptoms and the Clapham rail
accident. Carolyn Selley *et al*
478–482
Social networks, service use and
psychosis in South London. Thomas
Becker *et al* 15–19
- Suicide by age, ethnic group,
coroners' verdicts and country of
birth. Jan Neeleman *et al* 463–467
- Longevity**
Eugeria, longevity and normal ageing.
Karen Ritchie (Editorial) 501
- Lunacy Act (1890)**
Henry Rollin (*One hundred years ago*)
291–292, (*One hundred years ago*)
488–489
- Malingering**
Mark Turner (Editorial) 409–411
- Mania**
Lithium: balancing risks and benefits.
John Cookson (Evidence-based
psychiatry) 120–124
Lithium: evidence reconsidered.
Joanna Moncrieff (Evidence-based
psychiatry) 113–119
Postnatal depression and elation
among mothers and their partners.
A. Lane *et al* 550–555
- Marital status**
Gender and age at onset of
schizophrenia. L. E. DeLisi (C) 188
- Medical Outcomes Trust Short Form
36 (SF36)**
Disability, outcome and case-mix in
acute in-patient units. Brendon
Boot *et al* 242–246
- Medicine**
Psychiatry, and consultation-liaison.
Richard A. Mayou (Editorial)
203–204
- Memory**
Poor memory, negative symptoms and
abnormal movements in never-
treated Indian patients with
schizophrenia. R. G. McCreadie
et al 360–363
Subjective complaints in the elderly:
depressive symptoms and future
dementia. Ben Schmand *et al*
373–376
- Men**
Suicide among psychiatric in-patients.
H. G. Morgan & Ruth Stanton
561–563
Trends in deliberate self-harm in Oxford.
Keith Hawton *et al* 556–560
see also Fathers and Gender differences
- Mental health**
Long-term cannabis use. Wayne Hall
& Nadia Solowij (Editorial)
107–108
Urban environment. Odd Steffen
Dalgard & Kristian Tambs 530–536
- Mental health services**
Clinical and social outcome of stay in
small group homes. Thomas
Middelboe 251–255
- Comorbidity of mental disorders with
substance misuse. Francis Keaney
et al (C) 484–485
Costs of community care for older
people. Gill Livingston *et al* 56–59
Dual diagnosis of severe mental illness
and substance misuse: a case for
specialist services? Sonia Johnson
(Editorial) 205–208
Ethnic differences in satisfaction
among people with psychosis in
South London. Sue Parkman *et al*
260–264
Integration between primary and
secondary services in the care of
the severely mentally ill. Jonathan
Bindman *et al* 169–174
Needs assessment for mentally
disordered offenders. Andrea
Cohen and Nigel Eastman (Review
Article) 412–416
Prejudice against providers of services
for Black people. P. Harrison-Read
(C) 582
Provision for people with
schizophrenia. Fiona H. Lang *et al*
I. Clinical and economic
perspective 159–164
II. Role of the GP 165–168.
R. J. Simpson (C) 585.
F. H. Lang (Author's reply) (C)
585–586
Reports on psychotherapy
commissioned by the NHS
Executive. Anton Obholzer
(Editorial) 495–496
Social networks and use among
representative cases of psychosis in
South London. Thomas Becker *et al*
15–19
Trends in deliberate self-harm in
Oxford. Implications for
clinical services and prevention
of suicide. Keith Hawton *et al*
556–560
see also General practice, Hospitals
and In-patients
- Mental health surveys**
Sigmund: a European database.
C. Polge (C) 91
- Mental illness see** Psychiatric disorders
- Mentally disordered offenders see**
Offenders
- Mini Mental State Examination**
Age-related cognitive decline and
vision impairment affecting
detection of dementia syndrome.
Friedel M. Reischies & Bernhard
Geiselmann 449–451
Subjective memory complaints in
the elderly. Ben Schmand *et al*
373–376
- Mood disorders see** Affective disorders
- Morbidity**
Brazilian multicentric study of
psychiatric morbidity. Naomar
Almeida-Filho *et al* 524–529

- Mortality**
Excess mortality of schizophrenia. Steve Brown (*Review Article*) 502–508
Lethal lithium poisoning with sustained-release preparations. M. Hrdlicka & P. Sevcik (C) 586
Long-term mortality after first psychiatric admission. V. Hansen (C) 187. C. Stark *et al* (C) 187. A. S. Lee *et al* (*Authors' reply*) (C) 187–188
see also **Suicide**
- Moscow**
The Moscow meeting. Henry Rollin (*One hundred years ago*) 394
- Mother-to-infant bonding**
“Anybody’s child”: severe disorders of bonding. R. Channi Kumar 175–181. I. F. Brockington (C) 486
- Movement disorders**
Bereitschaftspotential in schizophrenia. T. Karaman *et al* 31–34
Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia. R. G. McCreadie *et al* 360–363
Spontaneous dyskinesia in schizophrenic and non-schizophrenic patients. Wayne S. Fenton *et al* 265–268
see also **Tardive dyskinesia**
- National Confidential Inquiry into Suicide and Homicide by People with Mental Illness**
L. Appleby *et al* (C) 391
- National Health Service**
Minor psychiatric disorder in NHS trust staff. T. D. Wall *et al* 519–523
- National Health Service Executive**
Reports on psychotherapy commissioned by the NHS Executive. Anton Obholzer (*Editorial*) 495–496
- Needs assessment**
For mentally disordered offenders. Andrea Cohen & Nigel Eastman (*Review Article*) 412–416
- Neuroleptics**
Atypical. Establishing cost-effectiveness. Glenn Robert & Peter Kennedy (*Editorial*) 103–104
Risk factors for severe tardive dyskinesia in older patients. Michael P. Caligiuri *et al* 148–153
Study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. J. C. Speller *et al* 564–568
see also **Antipsychotics** and individual names
- Neutropenia**
Leucopenia. Risperidone-induced. Z. Dernovsek and R. Tavcar (C) 393–394
- Nigeria**
Financial cost of treating out-patients with schizophrenia. Toyin G. Suleiman *et al* 364–368
- Noradrenaline**
Plasma noradrenaline response to ECT in depressive illness. C. B. Kelly & S. J. Cooper 182–186
- North Cheshire**
Weather conditions and fatal self-harm. Emad Salib & Nicola Gray 473–477
- Nottingham**
Incidence of schizophrenia. J. Brewin *et al* 140–144
- Number needed to detain**
S. Fleminger (C) 287
- Obsessive–compulsive disorder (OCD)**
Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350
Brain 5-HT function. N. A. Fineberg *et al* 280–282
Controlled trial of exposure and response prevention. Merran Lindsay *et al* 135–139
Remission of transsexualism after comorbid OCD improved with self-exposure therapy. Isaac M. Marks & David Mataix-Cols 389–390
- Offenders**
Crime, violence, and schizophrenia. P. Noble (C) 189–190
Needs assessment. Andrea Cohen & Nigel Eastman (*Review Article*) 412–416
Number needed to detain. S. Fleminger (C) 287
- Olanzapine**
5-HT_{2A} receptor occupancy *in vivo* and response to new antipsychotics. M. J. Travis *et al* (C) 290–291
- Old age see Elderly**
- One hundred years ago**
Henry Rollin
Lunacy in London and Edinburgh 91
Mental disease out-patients 587–588
Royal Lunatic Asylum, Montrose 190
The Lunacy Act, 1890, and its amendments 291–292, 488–489
The Moscow meeting 394
- Orbito-insular cortex**
5-HT₂ receptor imaging in major depression: focal changes. F. Biver *et al* 444–448
- Out-patients**
Cognitive therapy and pharmacotherapy in recurrent depression. I.-M. Blackburn & R. G. Moore 328–334
Family planning needs and STD risk behaviours of female psychiatric out-patients. John H. Coverdale *et al* 69–72
Financial cost of treating out-patients with schizophrenia in Nigeria. Toyin G. Suleiman *et al* 364–368
Mental disease out-patients. Henry Rollin (*One hundred years ago*) 587–588
- Overdose see Deliberate self-harm**
- Oxford**
Trends in deliberate self-harm, 1985 to 1995. Keith Hawton *et al* 556–560
- Pakistani immigrants**
Adverse social circumstances and depression in UK. Nusrat Husain *et al* 434–438
- Panic disorder with agoraphobia**
Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350
- Paracetamol**
Trends in deliberate self-harm in Oxford. Keith Hawton *et al* 556–560
- Paroxetine**
Withdrawal syndrome in a neonate. M. L. Dahl *et al* (C) 391–392
- Patients**
Family planning needs and STD risk behaviours of female psychiatric out-patients. John H. Coverdale *et al* 69–72
Integration between primary and secondary services in the care of the severely mentally ill: patients’ and GPs’ views. Jonathan Bindman *et al* 169–174
Listening to them. Linda Gask (*Editorial*) 301–302
Psychiatrists and their patients: views on forms of dress and address. Julia A. Gledhill *et al* 228–232
Subjective experience of schizophrenia and depression among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25
- Personal accounts**
Listening to patients. Linda Gask (*Editorial*) 301–302
- Personal Health Questionnaire**
Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438

Personality disorder

Psychopathology. Tourette's syndrome. Mary M. Robertson *et al* 283–286

Severe. Change in borderline symptoms one year after therapeutic community treatment. Bridget Dolan *et al* 274–279

Pharmacotherapy *see* Drugs

Phobias

Eye movement desensitisation and reprocessing v. exposure *in vivo* for spider-phobic children. Peter Muris *et al* 82–86

Positive and Negative Syndrome Scale

Poor memory, negative symptoms and abnormal movements in never-treated patients with schizophrenia. R. G. McCreadie *et al* 360–363

Positron emission tomography

5-HT₂ receptor imaging in major depression: focal changes in orbito-insular cortex. F. Biver *et al* 444–448

Post-traumatic stress disorder

Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350

Psychological consequences of road traffic accidents in children and adolescents. D. Fearnley (C) 393.

A. Di Gallo (*Author's reply*) (C) 393

Psychological debriefing for victims of acute burn trauma. Jonathan I. Bisson *et al* 78–81

Symptoms and the Clapham rail accident. Carolyn Selley *et al* 478–482

Pregnancy

Family planning needs and STD risk behaviours of female psychiatric out-patients. John H. Coverdale *et al* 69–72

Increased rate of psychosis among African-Caribbeans in Britain is not due to an excess of pregnancy and birth complications. G. Hutchinson *et al* 145–147

Maternal stress or anxiety and emotional development of the child. Vivette Glover (*Editorial*) 105–106

Present State Examination

Clinical and social outcome of stay in small group homes. Thomas Middelboe 251–255

Postpartum psychiatric illness in Arab culture. R. Ghubash & M. T. Abou-Saleh 65–68

Prevention

Strategies for preventing suicide. Glyn Lewis *et al* 351–354

Trends in deliberate self-harm in Oxford. Implications for clinical services and prevention of suicide. Keith Hawton *et al* 556–560

Primary care *see* General practice

Prion diseases

BSE and human prion disease. J. G. Longhurst (C) 290

PRiSM Study 4

Ethnic differences in satisfaction with mental health services among people with psychosis in South London. Sue Parkman *et al* 260–264

Psychiatric Assessment Schedule

Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438

Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433

Psychiatric disorders

Among the community-dwelling elderly in Dublin. Michael Kirby *et al* 369–372

Brazilian multicentric study of morbidity. Naomar Almeida-Filho *et al* 524–529

Clinical and social outcome of stay in small group homes. Thomas Middelboe 251–255

Clinical trials: severe mental illness and substance misuse. R. Laugharne (C) 587

Common mental disorders in primary care in Harare, Zimbabwe. V. Patel *et al* 60–64

Comorbidity with substance misuse. Wayne Hall & Michael Farrell (*Editorial*) 4–5. Francis Keaney *et al* (C) 484–485. I. H. A. Franken & V. M. Hendriks (C) 485

Determinants of GP recognition in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541

Dual diagnosis of severe mental illness and substance misuse. Sonia Johnson (*Editorial*) 205–208

Helpfulness of interventions: beliefs of health professionals compared with the general public. Anthony F. Jorm *et al* 233–237

Integration between primary and secondary services in the care of the severely mentally ill. Jonathan Bindman *et al* 169–174

Long-term mortality after first psychiatric admission. V. Hansen (C) 187. C. Stark *et al* (C) 187. A. S. Lee *et al* (*Authors' reply*) (C) 187–188

Lunacy in London and Edinburgh. Henry Rollin (*One hundred years ago*) 91

Mental disease out-patients. Henry Rollin (*One hundred years ago*) 587–588

Minor disorder in NHS trust staff. T. D. Wall *et al* 519–523

National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. L. Appleby *et al* (C) 391

Psychiatric journals

Publication trends of papers on schizophrenia. Analysis of three journals. Massimo Morlino *et al* 452–456

Psychiatrists

Their patients: views on forms of dress and address. Julia A. Gledhill *et al* 228–232

Psychiatry

Genetics. Michael J. Owen & Peter McGuffin (*Editorial*) 201–202

Medicine, and consultation–liaison. Richard A. Mayou (*Editorial*) 203–204

Opportunities from genetic findings. Michael Rutter & Robert Plomin (*Review Article*) 209–219

The Church. P. Daborn (C) 391

Transcending barriers between it and religion. D. Roberts (C) 188

Psychological debriefing

For victims of acute burn trauma. Jonathan I. Bisson *et al* 78–81.

G. Turnbull *et al* (C) 582.

J. I. Bisson & P. L. Jenkins (*Authors' reply*) (C) 583.

R. P. Kraus (C) 583. David Reiss & Morven Leese (C) 583–584

Psychosis

Dual diagnosis of severe mental illness and substance misuse. Sonia Johnson (*Editorial*) 205–208

Effects of level of socio-economic development on course of non-affective psychosis. Vijay K. Varma *et al* 256–259

Ethnic differences in satisfaction with mental health services in South London. Sue Parkman *et al* 260–264

Family involvement in care. An ethical argument. George I. Szmukler & Sidney Bloch (*Editorial*) 401–405

Increased rate among African-Caribbeans in Britain is not due to an excess of pregnancy and birth complications. G. Hutchinson *et al* 145–147

London–East Anglia randomised controlled trial of cognitive-behavioural therapy

I: Effects of treatment phase.

Elizabeth Kuipers *et al* 319–327

II: Predictors of outcome.

P. Garety *et al* 420–426

Long-term cannabis use and mental health. Wayne Hall & Nadia Solowij (*Editorial*) 107–108

Psychopathological syndromes and familial morbid risk. A. Ryan (C) 289. J. Van Os *et al* (*Authors' reply*) (C) 289

Social networks and service use among representative cases in South London. Thomas Becker *et al* 15–19

- Psychotherapy**
 Reports commissioned by the NHS Executive. Anton Obholzer (*Editorial*) 495–496
 Therapeutic community treatment for severe personality disorder. Bridget Dolan *et al* 274–279
see also Cognitive-behavioural therapy, Cognitive therapy and Psychological debriefing
- PTSD** *see* Post-traumatic stress disorder
- Public attitudes**
 Helpfulness of interventions for mental disorders. Anthony F. Jorm *et al* 233–237
- Puerperium**
 Postnatal depression and elation among mothers and their partners. A. Lane *et al* 550–555
 Postpartum psychiatric illness in Arab culture. R. Ghubash & M. T. Abou-Saleh 65–68
 Severe disorders of mother-to-infant bonding. R. Channi Kumar 175–181. I. F. Brockington (C) 486
- Quality of life**
 Subjective quality of life and drug treatment for schizophrenia. S. Sengupta and N. Kar (C) 587
 Subjective quality of life in schizophrenia. M. R. Agarwal (C) 392. M. Franz (*Author's reply*) (C) 392
- Questionnaires**
 General Health Questionnaire 26–30, 53–55, 519–523, 537–541
 Personal Health Questionnaire 434–438
 Self Report Questionnaire 65–68
- Rating scales** *see* Scales
- Refugees**
 Anxiety and depression in asylum-seekers. J. J. Rodenburg *et al* (C) 394
- Relatives** *see* Families
- Religion**
 Psychiatry and the Church. P. Daborn (C) 391
 Transcending barriers between it and psychiatry. D. Roberts (C) 188
- Research**
 Closing the gap between research and practice. John R. Geddes & Paul J. Harrison (*Evidence-based psychiatry*) 220–225. Invited commentaries. Ian Anderson *et al* (*Evidence-based psychiatry*) 226–227
- Publication trends of papers on schizophrenia. Analysis of three psychiatric journals. Massimo Morlino *et al* 452–456
- Research Diagnostic Criteria**
 Expressed emotion and depression. H. Hayhurst *et al* 439–443
- Risk assessment**
 Clinical risk management. C. Jones (C) 290
 Number needed to detain. S. Fleminger (C) 287
 Suicide among psychiatric in-patients. H. G. Morgan & Ruth Stanton 561–563
- Risperidone**
 Establishing cost-effectiveness of atypical neuroleptics. Glenn Robert & Peter Kennedy (*Editorial*) 103–104
 Induced leucopenia and neutropenia. Z. Dernovsek & R. Tavcar (C) 393–394
- Road traffic accidents**
 Driver suicides. Annakatri Ohberg *et al* 468–472
 Psychological consequences in children and adolescents. D. Fearnley (C) 393. A. Di Gallo (*Author's reply*) (C) 393
- Royal Lunatic Asylum, Montrose**
 Henry Rollin (*One hundred years ago*) 190
- Rural populations**
 Effects of level of socio-economic development on course of non-affective psychosis. Vijoy K. Varma *et al* 256–259
- Scales**
 Abnormal Involuntary Movements Scale 360–363
 Brief Psychiatric Rating Scale 319–327, 420–426, 569–573
 Clinical Anxiety Scale 427–433
 Edinburgh Postnatal Depression Scale 65–68, 550–555
 Hamilton Rating Scale for Depression 131–134, 427–433, 439–443, 569–573
 Health of the Nation Outcome Scales 242–246
 Highs Scale 550–555
 Hopelessness Scale 35–41
 Impact of Events Scale 478–482
 Leeds Scale for Depression and Anxiety 53–55
 Positive and Negative Syndrome Scale 360–363
 Scale for the Assessment of Negative Symptoms 569–573
 Scale for the Assessment of Positive Symptoms 569–573
- Wang Scale 340–345
 Wechsler Memory Scale 360–363
see also Beck Depression Inventory, Borderline Syndrome Index, Examinations, Geriatric Mental State (GMS)-AGECAT, Interviews, Medical Outcomes Trust Short Form 36, Questionnaires, Research Diagnostic Criteria, Schedules, Symptom Checklist and Tests
- Schedules**
 History and Aetiology Schedule 449–451
 Life Events and Difficulties Schedule 427–433, 434–438
 Psychiatric Assessment Schedule 427–433, 434–438
 Schedule for Affective Disorders and Schizophrenia 20–25
 Verona Service Satisfaction Schedule 260–264
- Schizoaffective disorder**
 Psychopathological syndromes and familial morbid risk of psychosis. A. Ryan (C) 289. J. Van Os *et al* (*Authors' reply*) (C) 289
- Schizophrenia**
Aetiology
 Cannabis. J. G. Longhurst (C) 584. W. Hall (*Author's reply*) (C) 584–585
 Gender and age at onset. L. E. DeLisi (C) 188
 Influenza. T. J. Crow (C) 91
Complications
 Crime and violence. P. Noble (C) 189–190
 Excess mortality. Steve Brown (*Review Article*) 502–508
 History of violent behaviour in different cultures. Jan Volavka *et al* 9–14
 Poor memory, negative symptoms and abnormal movements in never-treated Indian patients. R. G. McCreadie *et al* 360–363
 Risk factors for suicide in patients. C. D. Rossau & P. B. Mortensen 355–359
 Spontaneous dyskinesia in schizophrenic and non-schizophrenic patients. Wayne S. Fenton *et al* 265–268
- Course*
 Effects of level of socio-economic development on course of non-affective psychosis. Vijoy K. Varma *et al* 256–259
 Executive dysfunction and negative symptoms: apparent gender differences in 'static' v. 'progressive' profiles. Paul J. Scully *et al* 154–158
 Social course. A. Cohen & S. Lee (C) 287. T. Craig *et al* (*Authors' reply*) (C) 288

Epidemiology

Incidence in Nottingham. J. Brewin *et al* 140–144

Pathology

Grey matter correlates of syndromes. David E. Rous (C) 484

Pathophysiology

Altered dopaminergic function and negative symptoms in drug-free patients. M. B. Knable *et al* 574–577

Bereitschaftspotential. T. Karaman *et al* 31–34

Psychology

Appraisal, psychological adjustment and EE in relatives of patients. Christine Barrowclough & Michael Parle 26–30

Poor memory, negative symptoms and abnormal movements in never-treated Indian patients. R. G. McCreadie *et al* 360–363

Subjective experience among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25

Research

Publication trends of papers. Analysis of three psychiatric journals. Massimo Morlino *et al* 452–456

Therapy

Cost-effectiveness of clozapine. UK clinic-based study. Katherine J. Aitchison and Robert W. Kerwin 125–130

Costs. Martin Knapp (*Review Article*) 509–518

Financial cost of treating out-patients in Nigeria. Toyin G. Suleiman *et al* 364–368

Neuroleptic study of chronic in-patients characterised by persistent negative symptoms. J. C. Speller *et al* 564–568

Service provision. Fiona H. Lang *et al* I. Clinical and economic perspective 159–164

II. Role of the GP 165–168. R. J. Simpson (C) 585. F. H. Lang (*Author's reply*) (C) 585–586

Subjective quality of life and drug treatment. S. Sengupta & N. Kar (C) 587

Subjective quality of life. M. R. Agarwal (C) 392. M. Franz (*Author's reply*) (C) 392

Sulpiride augmentation in people partially responsive to clozapine. R. Shiloh *et al* 569–573

Screening Test for Co-Morbid Personality Disorders

Personality disorder in Tourette's syndrome. Mary M. Robertson *et al* 283–286

Seasonality

Changes in psychological well-being in an elderly population. John M. Eagles *et al* 53–55

Seclusion

Restraint, and emergency medication. H. Sequeira and S. Halstead (C) 288–289

Selective serotonin reuptake inhibitors

Cost-effectiveness of antidepressant treatment. L. Head & V. O'Keane (C) 88

Discontinuation rates of SSRIs and tricyclics. I. Anderson & C. Mortimore (C) 87. S. Lynch & S. Curran (C) 87. M. Hotopf *et al* (*Authors' reply*) (C) 87–88

Suicide and cost-effectiveness of antidepressants. S. Lynch (C) 189 *see also* Citalopram and Paroxetine

Self Report Questionnaire

Postpartum psychiatric illness in Arab culture. R. Ghubash & M. T. Abou-Saleh 65–68

Serotonin *see* 5-Hydroxytryptamine

Sertindole

5-HT_{2A} receptor occupancy *in vivo* and response to new antipsychotics. M. J. Travis *et al* (C) 290–291

Sex differences *see* Gender differences

Sexual disorders

Remission of transsexualism after comorbid OCD improved with self-exposure therapy. Isaac M. Marks & David Mataix-Cols 389–390

Sexual dysfunction

Citalopram-induced decreased libido. A. Michael & J. J. Herrod (C) 90

Sexually transmitted diseases

Family planning needs and risk behaviours of female psychiatric out-patients. John H. Coverdale *et al* 69–72

Sigmund

European database of mental health surveys. C. Polge (C) 91

Single photon emission computed tomography

Dopaminergic function and negative symptoms in schizophrenia. M. B. Knable *et al* 574–577

Single photon emission tomography

Brain blood flow in anxiety disorders. J. V. Lucey *et al* 346–350

Sleep disorders

DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction. Maurice M. Ohayon *et al* 382–388

Sleep disturbance and Huntington's disease. N. Taylor & D. Bramble (C) 393

Social factors

Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438

Outcome of anxiety and depressive disorders in primary care. Clare Ronalds *et al* 427–433

Prediction of psychiatric admission in different diagnostic groups. Anthony P. Boardman *et al* 457–462

Social networks and service use among representative cases of psychosis in South London. Thomas Becker *et al* 15–19

Urban environment and mental health. Odd Steffen Dalgard & Kristian Tambs 530–536

Social psychiatry

A very British kind of social psychiatry. Leon Eisenberg (*Review Article*, Michael Shepherd Memorial Symposium) 309–313

Socio-economic development

Effects on course of non-affective psychosis. Vijoy K. Varma *et al* 256–259

Somatic symptoms

Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438

Spider phobia

Eye movement desensitisation and reprocessing v. exposure *in vivo* for children. Peter Muris *et al* 82–86

SSRIs *see* Selective serotonin reuptake inhibitors

Stress

Maternal stress or anxiety in pregnancy and emotional development of the child. Vivette Glover (*Editorial*) 105–106

Structural neuroimaging

In learning disability. Shoumitro Deb (*Review Article*) 417–419

Structured Clinical Interview for DSM-III-R Personality Disorders II Personality disorder in Tourette's syndrome. Mary M. Robertson *et al* 283–286

Subjective experience

Listening to patients. Linda Gask (*Editorial*) 301–302

Schizophrenia and depression among US Latinos and Euro-Americans. Janis Hunter Jenkins 20–25

Substance misuse *see* Alcohol and Drug misuse

Suicide

Among psychiatric in-patients. H. G. Morgan & Ruth Stanton 561–563

By age, ethnic group, coroners' verdicts and country of birth. Jan Neeleman *et al* 463–467

Cost-effectiveness of antidepressants. S. Lynch (C) 189

Drivers. Annakatri Ohberger *et al* 468–472

Excess mortality of schizophrenia. Steve Brown (*Review Article*) 502–508

- Intensive in-patient and community intervention v. routine care after attempted suicide. Rob van der Sande *et al* 35–41
- Long-term mortality after first psychiatric admission. V. Hansen (C) 187. C. Stark *et al* (C) 187. A. S. Lee *et al* (*Authors' reply*) (C) 187–188
- National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. L. Appleby *et al* (C) 391
- One hundred cases of attempted suicide in the elderly. Jason Hepple & Catherine Quinton 42–46
- One hundred in-patient suicides. France Proulx *et al* 247–250
- Risk factors in patients with schizophrenia. C. D. Rossau & P. B. Mortensen 355–359
- Strategies for prevention. Glyn Lewis *et al* 351–354
- Substance misuse. Jan Neeleman & Michael Farrell (*Editorial*) 303–304
- Trends in deliberate self-harm in Oxford. Implications for clinical services and prevention of suicide. Keith Hawton *et al* 556–560
- Weather conditions and fatal self-harm in North Cheshire. Emad Salib & Nicola Gray 473–477
- Sulpiride**
- Augmentation in schizophrenia partially responsive to clozapine. R. Shiloh *et al* 569–573
- Symptom Checklist (SCL-90)**
- Care after attempted suicide. Rob van der Sande *et al* 35–41
- Comorbidity of mental disorders with substance misuse. I. H. A. Franken & V. M. Hendriks (C) 485
- Symptoms**
- Change in borderline symptoms after therapeutic community treatment for severe personality disorder. Bridget Dolan *et al* 274–279
- Dopaminergic function and negative symptoms in schizophrenia. M. B. Knable *et al* 574–577
- DSM-IV and ICD-90 insomnia symptoms and sleep dissatisfaction. Maurice M. Ohayon *et al* 382–388
- Executive dysfunction and negative symptoms in schizophrenia. Paul J. Scully *et al* 154–158
- Low-dose neuroleptics in chronic schizophrenia characterised by persistent negative symptoms. J. C. Speller *et al* 564–568
- Malingering. Mark Turner (*Editorial*) 409–411
- Poor memory, negative symptoms and abnormal movements in never-treated patients with schizophrenia. R. G. McCreadie *et al* 360–363
- PTSD symptoms and the Clapham rail accident. Carolyn Selley *et al* 478–482
- Somatic. Adverse social circumstances and depression in people of Pakistani origin in UK. Nusrat Husain *et al* 434–438
- Syndromes**
- Grey matter correlates of syndromes in schizophrenia. David E. Rous (C) 484
- Psychopathological syndromes and familial morbid risk of psychosis. A. Ryan (C) 289. J. Van Os *et al* (*Authors' reply*) (C) 289
- see also* **Chronic fatigue, Tourette's and Withdrawal**
- Tardive dyskinesia**
- CYP2D6 polymorphism in Chinese. S.-A. Chong (C) 586
- Severe. Incidence and risk factors in older patients. Michael P. Caligiuri *et al* 148–153
- Tests**
- Dutch Adult Reading Test 373–376
- Screening Test for Co-Morbid Personality Disorders 283–286
- Therapeutic community treatment**
- For severe personality disorder. Bridget Dolan *et al* 274–279
- Tourette's syndrome**
- Personality disorder and psychopathology. Mary M. Robertson *et al* 283–286
- Toxicity**
- Lethal lithium poisoning with sustained-release preparations. M. Hrdlicka and P. Sevcik (C) 586
- Transsexualism**
- Four-year remission after comorbid OCD improved with self-exposure therapy. Isaac M. Marks & David Mataix-Cols 389–390
- Trauma**
- Anxiety and depression in asylum-seekers. J. J. Rodenburg *et al* (C) 394
- Psychological consequences of road traffic accidents in children and adolescents. D. Fearnley (C) 393. A. Di Gallo (*Author's reply*) (C) 393
- Psychological debriefing for victims of acute burn trauma. Jonathan I. Bisson *et al* 78–81. G. Turnbull *et al* (C) 582. J. I. Bisson & P. L. Jenkins (*Authors' reply*) (C) 583. R. P. Kraus (C) 583. David Reiss & Morven Leese (C) 583–584
- PTSD symptoms and the Clapham rail accident. Carolyn Selley *et al* 478–482
- War pensions. M. Atkins & S. Davies (C) 188–189
- Tricyclics**
- Cost-effectiveness of antidepressant treatment. L. Head & V. O'Keane (C) 88
- Discontinuation rates of SSRIs and tricyclics. I. Anderson & C. Mortimore (C) 87. S. Lynch & S. Curran (C) 87. M. Hotopf *et al* (*Authors' reply*) (C) 87–88
- Suicide and cost-effectiveness of antidepressants. S. Lynch (C) 189
- Unipolar disorder**
- Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581
- United Kingdom**
- Adverse social circumstances and depression in people of Pakistani origin. Nusrat Husain *et al* 434–438
- Cost-effectiveness of clozapine. A clinic-based study. Katherine J. Aitchison and Robert W. Kerwin 125–130
- see also* **Britain**
- United States**
- Subjective experience of schizophrenia and depression among Latinos and Euro-Americans. Janis Hunter Jenkins 20–25
- Urban populations**
- Determinants of GP recognition of psychological problems in a multi-ethnic inner-city health district. S. M. Odell *et al* 537–541
- Effects of level of socio-economic development on course of non-affective psychosis. Vijoy K. Varma *et al* 256–259
- Urban environment and mental health. Odd Steffen Dalgard & Kristian Tambs 530–536
- Verona Service Satisfaction Schedule**
- Ethnic differences in satisfaction with mental health services. Sue Parkman *et al* 260–264
- Violence**
- Crime, violence, and schizophrenia. P. Noble (C) 189–190
- History of violent behaviour and schizophrenia in different cultures. Jan Volavka *et al* 9–14
- Number needed to detain. S. Fleming (C) 287
- Risk assessment and clinical risk management. C. Jones (C) 290
- Use of seclusion, restraint, and emergency medication. H. Sequeira & S. Halstead (C) 288–289

Vision impairment

Age-related cognitive decline and vision impairment affecting detection of dementia syndrome. Friedel M. Reischies & Bernhard Geiselmann 449–451

Wang Scale

Rapid intravenous detoxification in heroin addicts. Albert Seoane *et al* 340–345

War pensions

M. Atkins & S. Davies (C) 188–189

Weather

Fatal self-harm in North Cheshire. Emad Salib & Nicola Gray 473–477

Wechsler Memory Scale

Poor memory, negative symptoms and abnormal movements in never-treated patients with schizophrenia. R. G. McCreadie *et al* 360–363

Withdrawal syndromes

Paroxetine withdrawal syndrome in a neonate. M. L. Dahl *et al* (C) 391–392

Women

Common mental disorders in primary care in Harare, Zimbabwe. V. Patel *et al* 60–64

Disorders of the mother–infant relationship. I. F. Brockington (C) 486

Family planning needs and STD risk behaviours of psychiatric out-patients. John H. Coverdale *et al* 69–72

Seasonal well-being in the elderly. John M. Eagles *et al* 53–55

Severe disorders of mother-to-infant bonding. R. Channi Kumar 175–181
see also Gender differences, Girls, Pregnancy and Puerperium

World Health Organization

Study on Determinants of Outcome of Severe Mental Disorders
Social course of schizophrenia. A. Cohen & S. Lee (C) 287.
T. Craig *et al* (Authors' reply) (C) 288

Violent behaviour and schizophrenia. Jan Volavka *et al* 9–14

X chromosome

Test of Xq26.3–28 linkage in bipolar and unipolar families. C. Smyth *et al* 578–581

Zimbabwe

Common mental disorders in primary care in Harare. V. Patel *et al* 60–64

PART II. CONTRIBUTORS

Abou-Saleh, M. T. *see* Ghubash, R. 65–68

Acuda, W. *see* Patel, V. *et al* 60–64

Adams, Clive E. Establishing cost-effectiveness of antipsychotic drugs (C) 486

Adityanjee, M. D. *et al*. Eosinophilia, agranulocytosis and clozapine (C) 485–486

Adshead, G. *see* Lucey, J. V. *et al* 346–350

Agarwal, M. R. Subjective quality of life in schizophrenia (C) 392

Ahlner, J. *see* Dahl, M. L. *et al* (C) 391–392

Aitchison, K. J. *see* Kerwin, R. W. (C) 584

Aitchison, Katherine J. & Kerwin, Robert W. Cost-effectiveness of clozapine. A UK clinic-based study 125–130

Aizenberg, D. *see* Shiloh, R. *et al* 569–573

Albert, Maya *see* Becker, Thomas *et al* 15–19

Alberts, J. L. *see* Speller, J. C. *et al* 564–568

Alexander, Julie *see* Bisson, Jonathan I. *et al* 78–81

Allart, Esther *see* van der Sande, Rob *et al* 35–41

Allen, Keith *see* Boardman, Anthony P. *et al* 457–462

Allen, R. L. *et al*. Neuropsychological and imaging differences in dementia with Lewy bodies and Alzheimer's disease (C) 486–487

Almeida-Filho, Naomar *et al*. Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates 524–529

Álvarez, Miguel *see* Seoane, Albert *et al* 340–345

Amos, T. *see* Appleby, L. *et al* (C) 391

Anderson, I. & Mortimore, C. Discontinuation rates of SSRIs and tricyclic antidepressants (C) 87

Anderson, Ian *et al*. Invited commentaries on: Closing the gap between research and practice (*Evidence-based psychiatry*) 226–227

Andreoli, Sérgio Baxter *see* Almeida-Filho, Naomar *et al* 524–529

Andrews, Gavin *see* Boot, Brendon *et al* 242–246

Andrews, Gavin *see* Lindsay, Merran *et al* 135–139

Appleby, L. *et al*. Confidential Inquiry into Suicide and Homicide by People with Mental Illness (C) 391

Atkins, M. and Davies, S. War pensions (C) 188–189

Ayankaran, J. R. *see* McCreadie, R. G. *et al* 360–363

Bailey, P. Clozapine treatment, eosinophilia and agranulocytosis (C) 90

Baker, Sherryl *see* Volavka, Jan *et al* 9–14

Bale, Elizabeth *see* Hawton, Keith *et al* 556–560

Banerjee, Sube *see* Robertson, Mary M. *et al* 283–286

Bannister, Carol *see* Bisson, Jonathan I. *et al* 78–81

Barnes, T. R. E. *see* Speller, J. C. *et al* 564–568

Barrowclough, Christine & Parle, Michael. Appraisal, psychological adjustment and expressed emotion in relatives of patients suffering from schizophrenia 26–30

Barry, S. *see* Lane, A. *et al* 550–555

Bearn, Jenny *see* Keaney, Francis *et al* (C) 484–485

Bebbington, P. *see* Garety, P. *et al* 420–426

Bebbington, Paul *see* Bindman, Jonathan *et al* 169–174
Bebbington, Paul *see* Kuipers, Elizabeth *et al* 319–327

Becker, Thomas *et al*. Social networks and service use among representative cases of psychosis in South London 15–19

Bernadt, M. & Stein, G. Lithium: evidence reconsidered (C) 484

Bhugra, D. *see* Hutchinson, G. *et al* 145–147

Bindman, Jonathan *et al*. Integration between primary and secondary services in the care of the severely mentally ill: patients' and general practitioners' views 169–174

Bird, Kevin D. *see* Vollmer-Conna, Ute *et al* 377–381

Bisson, J. I. & Jenkins, P. L. Psychological debriefing for victims of acute burn trauma (Authors' reply) (C) 583

Bisson, Jonathan I. *et al*. Randomised controlled trial of psychological debriefing for victims of acute burn trauma 78–81

Biver, F. *et al*. Serotonin 5-HT₂ receptor imaging in major depression: focal changes in orbito-insular cortex 444–448

Blackburn, I.-M. & Moore, R. G. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in out-patients with recurrent depression 328–334

Bloch, Sidney *see* Szmukler, George I. (Editorial) 401–405

Blyler, Crystal R. *see* Fenton, Wayne S. *et al* 265–268

- Boardman, Anthony P. *et al.* Social indicators and the prediction of psychiatric admission in different diagnostic groups 457–462
- Bolden, R. I. *see* Wall, T. D. *et al* 519–523
- Bond, Alison *see* Hawton, Keith *et al* 556–560
- Boneham, M. A. *see* McCracken, C. F. M. *et al* 269–273
- Boot, Brendon *et al.* Disability, outcome and case-mix in acute psychiatric in-patient units 242–246
- Borrill, C. S. *see* Wall, T. D. *et al* 519–523
- Bouman, W. P. *see* Pinner, G. (C) 289
- Bramble, D. *see* Taylor, N. (C) 393
- Breslau, Naomi *see* Peterson, Edward L. (C) 487–488
- Brewin, J. *et al.* Incidence of schizophrenia in Nottingham. A comparison of two cohorts, 1978 to 1980 and 1992 to 1994. 140–144
- Brockington, I. F. Disorders of the mother–infant relationship (C) 486
- Brown, Alan S. *see* Varma, Vijoy K. *et al* 256–259
- Brown, Steve. Excess mortality of schizophrenia. A meta-analysis (*Review Article*) 502–508
- Bruce, Irene *see* Kirby, Michael *et al* 369–372
- Brynjolfsson, J. *see* Smyth, C. *et al* 578–581
- Buckley, A. *see* Lee, A. S. *et al* (*Authors' reply*) (C) 187–188
- Busatto, G. *see* Lucey, J. V. *et al* 346–350
- Busatto, G. F. *see* Travis, M. J. *et al* (C) 290–291
- Buskens, Erik *see* van der Sande, Rob *et al* 35–41
- Busnello, Ellis D'Arrigo *see* Almeida-Filho, Naomar *et al* 524–529
- Busuttil, W. *see* Turnbull, G. *et al* (C) 582
- Büyükerberker, C. *see* Karaman, T. *et al* 31–34
- Byram, Victoria *see* North, Clive *et al* 545–549
- Cabré, Lluís *see* Seoane, Albert *et al* 340–345
- Caligiuri, Michael P. *et al.* Incidence and risk factors for severe tardive dyskinesia in older patients 148–153
- Cantwell, R. *see* Brewin, J. *et al* 140–144
- Carrasco, Genís *see* Seoane, Albert *et al* 340–345
- Carter, A. J. *see* Wall, T. D. *et al* 519–523
- Calet, Malijai *see* Ohayon, Maurice M. *et al* 382–388
- Chemerinski, Erán *see* Starkstein, Sergio E. *et al* 47–52
- Chong, S.-A. Tardive dyskinesia and CYP2D6 polymorphism in Chinese (C) 586
- Chong, S. A. & Chua, L. Clozapine, Chinese and blood (C) 89–90
- Christensen, Helen *see* Jorm, Anthony F. *et al* 233–237
- Chua, L. *see* Chong, S. A. (C) 89–90
- Cleave, N. *see* McCracken, C. F. M. *et al* 269–273
- Coakley, Davis *see* Kirby, Michael *et al* 369–372
- Coakley, Grainne *see* Scully, Paul J. *et al* 154–158
- Cohen, A. and Lee, S. Social course of schizophrenia (C) 287
- Cohen, Andrea and Eastman, Nigel. Needs assessment for mentally disordered offenders and others requiring similar services. Theoretical issues and a methodological framework (*Review Article*) 412–416
- Coleman, Ken *see* Koffman, Jonathan *et al* 238–241
- Commander, M. J. *see* Odell, S. M. *et al* 537–541
- Cookson, John. Lithium: balancing risks and benefits (*Evidence-based psychiatry*) 120–124
- Cooper, Peter J. & Goodyer, Ian. Prevalence and significance of weight and shape concerns in girls aged 11 to 16 years 542–544
- Cooper, S. J. *see* Kelly, C. B. 182–186
- Cooper, Z. *see* Hayhurst, H. *et al* 439–443
- Copeland, J. R. M. *see* McCracken, C. F. M. *et al* 269–273
- Coppola, R. *see* Knable, M. B. *et al* 574–577
- Costa, D. C. *see* Lucey, J. V. *et al* 346–350
- Costa, D. C. *see* Travis, M. J. *et al* (C) 290–291
- Costa, Josep *see* Seoane, Albert *et al* 340–345
- Coutinho, Evandro *see* Almeida-Filho, Naomar *et al* 524–529
- Coverdale, John H. *et al.* Family planning needs and STD risk behaviours of female psychiatric out-patients 69–72
- Cowen, P. J. *see* Fineberg, N. A. *et al* 280–282
- Craig, T. *et al.* Social course of schizophrenia (*Authors' reply*) (C) 288
- Creed, Francis *see* Husain, Nusrat *et al* 434–438
- Creed, Francis *see* Ronalds, Clare *et al* 427–433
- Crimlisk, Helen *see* Keaney, Francis *et al* (C) 484–485
- Crino, Rocco *see* Lindsay, Merran *et al* 135–139
- Crow, T. J. Influenza and schizophrenia (C) 91
- Curran, S. *see* Lynch, S. (C) 87
- Curson, D. A. *see* Speller, J. C. *et al* 564–568
- Curtis, D. *see* Smyth, C. *et al* 578–581
- Czobor, Pal *see* Volavka, Jan *et al* 9–14
- Daborn, P. Psychiatry and the Church (C) 391
- Dahl, M. L. *et al.* Paroxetine withdrawal syndrome in a neonate (C) 391–392
- Dalgard, Odd Steffen & Tambs, Kristian. Urban environment and mental health. A longitudinal study 530–536
- Dalkin, T. *see* Brewin, J. *et al* 140–144
- Damhaut, P. *see* Biver, F. *et al* 444–448
- Davies, S. *see* Atkins, M. (C) 188–189
- Davies, S. *see* Lee, A. S. *et al* (*Authors' reply*) (C) 187–188
- Davies, Sara *see* Parkman, Sue *et al* 260–264
- Dawe, Sharon *see* Strang, John *et al* 335–339
- Deahl, M. *see* Lucey, J. V. *et al* 346–350
- Deahl, Martin & Turner, Trevor. General psychiatry in no-man's land (*Editorial*) 6–8
- Deb, Shoumitro. Structural neuroimaging in learning disability (*Review Article*) 417–419
- de Girolamo, Giovanni *see* Morlino, Massimo *et al* 452–456
- DeLisi, L. E. Gender and age at onset of schizophrenia (C) 188
- Derksen, P. *see* Heeren, T. J. *et al* (*Authors' reply*) (C) 289–290
- Dernovsek, Z. & Tavcar, R. Risperidone-induced leucopenia and neutropenia (C) 393–394
- Di Gallo, A. Psychological consequences of road traffic accidents in children and adolescents (*Author's reply*) (C) 393
- Dolan, Bridget *et al.* Change in borderline symptoms one year after therapeutic community treatment for severe personality disorder 274–279
- Dorfman-Etrog, P. *see* Shiloh, R. *et al* 569–573
- Douglas, A. Stuart *see* Eagles, John M. *et al* 53–55
- Dunn, G. *see* Garety, P. *et al* 420–426
- Dunn, Graham *see* Kuipers, Elizabeth *et al* 319–327
- Eagles, John M. *et al.* Seasonal changes in psychological well-being in an elderly population 53–55

- Eastman, Nigel *see* Cohen, Andrea (Review Article) 412–416
- Egan, M. F. *see* Knable, M. B. *et al* 574–577
- Eisenberg, Leon. A very British kind of social psychiatry (Review Article, Michael Shepherd Memorial Symposium) 309–313
- Ell, P. J. *see* Lucey, J. V. *et al* 346–350
- Ell, P. J. *see* Travis, M. J. *et al* (C) 290–291
- Fagg, Joan *see* Hawton, Keith *et al* 556–560
- Fahy, T. A. *see* Hutchinson, G. *et al* 145–147
- Fahy, Tom *see* Howard, Louise (Editorial) 497–500
- Faria, F. Souza. General psychiatry in no-man's land (C) 483
- Farrell, Michael *see* Hall, Wayne (Editorial) 4–5
- Farrell, Michael *see* Neeleman, Jan (Editorial) 303–304
- Fearnley, D. Psychological consequences of road traffic accidents in children and adolescents (C) 393
- Fenton, Wayne S. *et al.* Prevalence of spontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients 265–268
- Fernandes, Jefferson *see* Almeida-Filho, Naomar *et al* 524–529
- Fineberg, N. A. *et al.* Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine 280–282
- Fleminger, S. Number needed to detain (C) 287
- Forbes, John F. *see* Lang, Fiona H. *et al* 159–164
- Fowler, D. *see* Garety, P. *et al* 420–426
- Fowler, David *see* Kuipers, Elizabeth *et al* 319–327
- Fox, R. *see* Brewin, J. *et al* 140–144
- Fox Hiley, Paul J. *see* Robertson, Mary M. *et al* 283–286
- França, Josimar Farias *see* Almeida-Filho, Naomar *et al* 524–529
- Franken, I. H. A. and Hendriks, V. M. Comorbidity of mental disorders with substance misuse (C) 485
- Franz, M. Subjective quality of life in schizophrenia (Author's reply) (C) 392
- Freeman, D. *see* Garety, P. *et al* 420–426
- Freeman, Daniel *see* Kuipers, Elizabeth *et al* 319–327
- Fulop, Naomi J. *see* Koffman, Jonathan *et al* 238–241
- Gacinovic, S. *see* Lucey, J. V. *et al* 346–350
- Gacinovic, S. *see* Travis, M. J. *et al* (C) 290–291
- Garety, P. *et al.* London–East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. II: Predictors of outcome 420–426
- Garety, Philippa *see* Kuipers, Elizabeth *et al* 319–327
- Gask, Linda. Listening to patients (Editorial) 301–302
- Gavrilovic, M. *see* Pelc, I. *et al* 73–77
- Geddes, J. R. *see* Powell, J. A. (C) 586–587
- Geddes, John R. & Harrison, Paul J. Closing the gap between research and practice (Evidence-based psychiatry) 220–225
- Geerlings, Mirjam I. *see* Schmand, Ben *et al* 373–376
- Geiselmann, Bernhard *see* Reischies, Friedel M. 449–451
- Ghubash, R. and Abou-Saleh, M. T. Postpartum psychiatric illness in Arab culture: prevalence and psychosocial correlates 65–68
- Gilbody, Simon M. *see* Anderson, Ian *et al* (Evidence-based psychiatry) 226–227
- Gilvarry, C. *see* Hutchinson, G. *et al* 145–147
- Gilvarry, K. *see* Van Os, J. *et al* (Authors' reply) (C) 289
- Glazebrook, C. *see* Brewin, J. *et al* 140–144
- Gledhill, Julia A. *et al.* Psychiatrists and their patients: views on forms of dress and address 228–232
- Glover, Vivette. Maternal stress or anxiety in pregnancy and emotional development of the child (Editorial) 105–106
- Gogliettino, Angela *see* Morlino, Massimo *et al* 452–456
- Goldman, S. *see* Biver, F. *et al* 444–448
- Golya, D. A. *see* Wall, T. D. *et al* 519–523
- Goodyer, Ian *see* Cooper, Peter J. 542–544
- Gorey, J. *see* Knable, M. B. *et al* 574–577
- Gossop, Michael *see* Strang, John *et al* 335–339
- Gowers, Simon *see* North, Clive *et al* 545–549
- Gray, Jeffrey *see* Strang, John *et al* 335–339
- Gray, Nicola *see* Salib, Emad 473–477
- Grunberg, Frédéric *see* Proulx, France *et al* 247–250
- Guilleminault, Christian *see* Ohayon, Maurice M. *et al* 382–388
- Gurling, H. *see* Smyth, C. *et al* 578–581
- Gwanzura, F. *see* Patel, V. *et al* 60–64
- Hadley, C. *see* Garety, P. *et al* 420–426
- Hadley, Clare *see* Kuipers, Elizabeth *et al* 319–327
- Hall, W. Cannabis and schizophrenia (Author's reply) (C) 584–585
- Hall, Wayne *see* Boot, Brendon *et al* 242–246
- Hall, Wayne and Farrell, Michael. Comorbidity of mental disorders with substance misuse (Editorial) 4–5
- Hall, Wayne & Solowij, Nadia. Long-term cannabis use and mental health (Editorial) 107–108
- Halstead, S. *see* Sequeira, H. (C) 288–289
- Hansen, V. Long-term mortality after first psychiatric admission (C) 187
- Hardy, G. E. *see* Wall, T. D. *et al* 519–523
- Hardy, R. *see* Hotopf, M. *et al* (Authors' reply) (C) 87–88
- Harrison, G. *see* Brewin, J. *et al* 140–144
- Harrison, Paul J. *see* Geddes, John R. (Evidence-based psychiatry) 220–225
- Harrison-Read, P. Prejudice against providers of psychiatric services for Black people (C) 582
- Haruna, Adam Y. *see* Suleiman, Toyin G. *et al* 364–368
- Hawton, Keith *see* Lewis, Glyn *et al* 351–354
- Hawton, Keith *see* van der Sande, Rob *et al* 35–41
- Hawton, Keith *et al.* Trends in deliberate self-harm in Oxford, 1985 to 1995. Implications for clinical services and the prevention of suicide 556–560
- Hayhurst, H. *et al.* Expressed emotion and depression. A longitudinal study 439–443
- Haynes, C. E. *see* Wall, T. D. *et al* 519–523
- Head, L. and O'Keane, V. Cost-effectiveness of antidepressant treatment (C) 88
- Heeren, T. J. *et al.* Treatment, outcome and predictors of response in elderly depressed in-patients (Authors' reply) (C) 289–290
- Heinz, A. *see* Knable, M. B. *et al* 574–577
- Henderson, Scott *see* Jorm, Anthony F. *et al* 233–237
- Hendriks, V. M. *see* Franken, I. H. A. (C) 485
- Hepple, Jason and Quinton, Catherine. One hundred cases of attempted suicide in the elderly 42–46
- Hernández, Eustaqui *see* Seoane, Albert *et al* 340–345
- Herrod, J. J. *see* Michael, A. (C) 90
- Heycop Ten Ham, B. F. v. *see* Heeren, T. J. *et al* (Authors' reply) (C) 289–290

- Hickie, Ian *see* Vollmer-Conna, Ute *et al* 377–381
- Hodgson, Richard E. *see* Boardman, Anthony P. *et al* 457–462
- Hopper, K. *see* Craig, T. *et al* (*Authors' reply*) (C) 288
- Hotopf, M. *et al.* Discontinuation rates of SSRIs and tricyclic antidepressants (*Authors' reply*) (C) 87–88
- Hovens, J. E. *see* Rodenburg, J. J. *et al* (C) 394
- Howard, Louise and Fahy, Tom. Liver transplantation for alcoholic liver disease (*Editorial*) 497–500
- Howard, Robert and Rabins, Peter. Late paraphrenia revisited (*Editorial*) 406–408
- Hrdlicka, M. and Sevcik, P. Lethal lithium poisoning with sustained-release preparations (C) 586
- Husain, Nusrat *et al.* Adverse social circumstances and depression in people of Pakistani origin in the UK 434–438
- Hutchinson, G. *et al.* Increased rate of psychosis among African–Caribbeans in Britain is not due to an excess of pregnancy and birth complications 145–147
- Jacomb, Patricia A. *see* Jorm, Anthony F. *et al* 233–237
- Jampala, V. Chowdary *see* Adityanjee, M. D. *et al* (C) 485–486
- Jelicic, M. and Kempen, G. I. J. M. Cognitive function and fall-related fractures (C) 88–89
- Jenkins, Janis Hunter. Subjective experience of persistent schizophrenia and depression among US Latinos and Euro-Americans 20–25
- Jenkins, P. L. *see* Bisson, J. I. (*Authors' reply*) (C) 583
- Jenkins, Peter L. *see* Bisson, Jonathan I. *et al* 78–81
- Jeste, Dilip V. *see* Caligiuri, Michael P. *et al* 148–153
- Johnson, Sonia *see* Becker, Thomas *et al* 15–19
- Johnson, Sonia *see* Bindman, Jonathan *et al* 169–174
- Johnson, Sonia. Dual diagnosis of severe mental illness and substance misuse: a case for specialist services? (*Editorial*) 205–208
- Johnstone, Eve C. *see* Lang, Fiona H. *et al* 159–164, 165–168
- Jones, C. Risk assessment and clinical risk management (C) 290
- Jones, P. *see* Van Os, J. *et al* (*Authors' reply*) (C) 289
- Jones, Peter *see* Lewis, Glyn *et al* 351–354
- Jones, Roger *see* Scott, Christine *et al* 131–134
- Jones, S. *see* Garety, P. *et al* 420–426
- Jonker, Cees *see* Schmand, Ben *et al* 373–376
- Jorm, Anthony F. *et al.* Helpfulness of interventions for mental disorders: beliefs of health professionals compared with the general public 233–237
- Kalsi, G. *see* Smyth, C. *et al* 578–581
- Kar, N. *see* Sengupta, S. (C) 587
- Karaman, T. *et al.* Bereitschaftspotential in schizophrenia 31–34
- Katona, C. L. E. *see* Allen, R. L. *et al* 486–487
- Katona, Cornelius *see* Livingston, Gill *et al* 56–59
- Keaney, Francis *et al.* Comorbidity of mental disorders with substance misuse (C) 484–485
- Kelly, C. B. and Cooper, S. J. Plasma noradrenaline response to electroconvulsive therapy in depressive illness 182–186
- Kempen, G. I. J. M. *see* Jelicic, M. (C) 88–89
- Kennedy, Peter *see* Robert, Glenn (*Editorial*) 103–104
- Kerwin, R. W. *see* Lucey, J. V. *et al* 346–350
- Kerwin, R. W. *see* Travis, M. J. *et al* (C) 290–291
- Kerwin, R. W. and Aitchison, K. J. Cost-effectiveness of clozapine (C) 584
- Kerwin, Robert W. *see* Aitchison, Katherine J. 125–130
- Kessler, Ronald C. Large same-year effects: fact or artefact? (*Author's reply*) (C) 488
- Keville, R. *see* Lane, A. *et al* 550–555
- Khaikin, M. *see* Shiloh, R. *et al* 569–573
- Khare, C. B. *see* Varma, Vijoy K. *et al* 256–259
- King, Elizabeth *see* Selley, Carolyn *et al* 478–482
- King, Michael *see* Gledhill, Julia A. *et al* 228–232
- Kinsella, A. *see* Lane, A. *et al* 550–555
- Kinsella, Anthony *see* Scully, Paul J. *et al* 154–158
- Kirby, Michael *et al.* Mental disorders among the community-dwelling elderly in Dublin 369–372
- Kleijn, W. C. *see* Rodenburg, J. J. *et al* (C) 394
- Knable, M. B. *et al.* Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. [¹²³I]-iodobenzamide SPECT study 574–577
- Knapp, Martin. Costs of schizophrenia (*Review Article*) 509–518
- Koffman, Jonathan *et al.* Ethnicity and use of acute psychiatric beds: one-day survey in North and South Thames regions 238–241
- Korten, Ailsa E. *see* Jorm, Anthony F. *et al* 233–237
- Kraus, R. P. Psychological debriefing for victims of acute burn trauma (C) 583
- Krivelevich, Ilya *see* Volavka, Jan *et al* 9–14
- Kuipers, E. *see* Garety, P. *et al* 420–426
- Kuipers, Elizabeth *see* Bindman, Jonathan *et al* 169–174
- Kuipers, Elizabeth *et al.* London–East Anglia randomised controlled trial of cognitive–behavioural therapy for psychosis. I: Effects of the treatment phase 319–327
- Kumar, R. Channi. “Anybody’s child”: severe disorders of mother-to-infant bonding 175–181
- Kuzis, Gabriela *see* Starkstein, Sergio E. *et al* 47–52
- Kwecinski, R. *see* Brewin, J. *et al* 140–144
- Lacro, Jonathan P. *see* Caligiuri, Michael P. *et al* 148–153
- Lane, A. *et al.* Postnatal depression and elation among mothers and their partners: prevalence and predictors 550–555
- Lang, F. H. Role of GPs in service provision for people with schizophrenia (*Author's reply*) (C) 585–586
- Lang, Fiona H. *et al.* Service provision for people with schizophrenia
I. Clinical and economic perspective 159–164
II. Role of the general practitioner 165–168
- Laska, Eugene *see* Volavka, Jan *et al* 9–14
- Latha, S. *see* McCreadie, R. G. *et al* 360–363
- Laugharne, R. Clinical trials: severe mental illness and substance misuse (C) 587
- Lawal, Rahman A. *see* Suleiman, Toyin G. *et al* 364–368
- Lawlor, Brian A. *see* Kirby, Michael *et al* 369–372
- Le Bon, O. *see* Pelc, I. *et al* 73–77
- Lee, A. S. *et al.* Long-term mortality after first psychiatric admission (*Authors' reply*) (C) 187–188
- Lee, K. S. *see* Knable, M. B. *et al* 574–577
- Lee, S. *see* Cohen, A. (C) 287
- Leese, Morven *see* Becker, Thomas *et al* 15–19

- Leese, Morven *see* Parkman, Sue *et al* 260–264
- Leese, Morven *see* Reiss, David (C) 583–584
- Leff, J. *see* Hutchinson, G. *et al* 145–147
- Lehert, P. *see* Pelc, I. *et al* 73–77
- Leiguarda, Ramón *see* Starkstein, Sergio E. *et al* 47–52
- Lemon, Jim *see* Vollmer-Conna, Ute *et al* 377–381
- Lesage, Alain D. *see* Proulx, France *et al* 247–250
- Lewis, G. *see* Hotopf, M. *et al* (*Authors' reply*) (C) 87–88
- Lewis, Glyn *see* Anderson, Ian *et al* (*Evidence-based psychiatry*) 226–227
- Lewis, Glyn *et al*. Strategies for preventing suicide 351–354
- Lewis, Martyn *see* Boardman, Anthony P. *et al* 457–462
- Lin, S. *see* Craig, T. *et al* (*Authors' reply*) (C) 288
- Lindeboom, Jaap *see* Schmand, Ben *et al* 373–376
- Lindsay, Merran *et al*. Controlled trial of exposure and response prevention in obsessive-compulsive disorder 135–139
- Lion, K. *see* Pelc, I. *et al* 73–77
- Lisanti, Felice *see* Morlino, Massimo *et al* 452–456
- Livingston, Gill *et al*. Costs of community care for older people 56–59
- Lloyd, Andrew *see* Vollmer-Conna, Ute *et al* 377–381
- Longhurst, J. G. BSE and human prion disease (C) 290
- Longhurst, J. G. Cannabis and schizophrenia (C) 584
- Lonnqvist, Jouko *see* Ohberg, Annakatri *et al* 468–472
- Lotstra, F. *see* Biver, F. *et al* 444–448
- Lucey, J. V. *et al*. Brain blood flow in anxiety disorders. OCD, panic disorder with agoraphobia, and post-traumatic stress disorder on 99m TcHMPAO single photon emission tomography (SPET) 346–350
- Lynch, S. Suicide and the cost-effectiveness of antidepressants (C) 189
- Lynch, S. and Curran, S. Discontinuation rates of SSRIs and tricyclic antidepressants (C) 87
- McAdams, Lou Ann *see* Caligiuri, Michael P. *et al* 148–153
- McCracken, C. F. M. *et al*. Prevalence of dementia and depression among people in Black and ethnic minorities 269–273
- McCreadie, R. G. *et al*. Poor memory, negative symptoms and abnormal movements in never-treated Indian patients with schizophrenia 360–363
- McCrone, Paul *see* Becker, Thomas *et al* 15–19
- McCrone, Paul and Thornicroft, Graham. Health economics (*Reading about*) 191–193
- McGlashan, Thomas H. *see* Fenton, Wayne S. *et al* 265–268
- McGuffin, Peter *see* Owen, Michael J. (*Editorial*) 201–202
- McKibbin, P. *see* McCracken, C. F. M. *et al* 269–273
- McLeod, Isabella H. *see* Eagles, John M. *et al* 53–55
- MacLeod, M. *see* Stark, C. *et al* (C) 187
- Mak, Vivienne *see* Neeleman, Jan *et al* 463–467
- Mallett, R. *see* Hutchinson, G. *et al* 145–147
- Manela, Monica *see* Livingston, Gill *et al* 56–59
- Mann, A. *see* Patel, V. *et al* 60–64
- Mann, Anthony. The evolving face of psychiatric epidemiology (*Review Article, Michael Shepherd Memorial Symposium*) 314–318
- Marcelis, M. *see* Van Os, J. *et al* (*Authors' reply*) (C) 289
- Mari, Jair de Jesus *see* Almeida-Filho, Naomar *et al* 524–529
- Marks, I. M. *see* Lucey, J. V. *et al* 346–350
- Marks, Isaac *see* Strang, John *et al* 335–339
- Marks, Isaac M. & Mataix-Cols, David. Four-year remission of transsexualism after comorbid obsessive-compulsive disorder improved with self-exposure therapy. Case report 389–390
- Martin, Nick *see* Selley, Carolyn *et al* 478–482
- Mataix-Cols, David *see* Marks, Isaac M. 389–390
- Mayer, Birgit *see* Muris, Peter *et al* 82–86
- Mayou, Richard A. Psychiatry, medicine and consultation-liaison (*Editorial*) 203–204
- Medley, I. *see* Brewin, J. *et al* 140–144
- Meisner, Morris *see* Volavka, Jan *et al* 9–14
- Mendlewicz, J. *see* Biver, F. *et al* 444–448
- Menon, D. K. *see* Varma, Vijoy K. *et al* 256–259
- Merckelbach, Harald *see* Muris, Peter *et al* 82–86
- Merskey, H. Tests of 'dissociation' and mood disorder (C) 487
- Mertens, J. *see* Travis, M. J. *et al* (C) 290–291
- Michael, A. and Herrod, J. J. Citalopram-induced decreased libido (C) 90
- Middelboe, Thomas. Prospective study of clinical and social outcome of stay in small group homes for people with mental illness 251–255
- Miller, Bruce L. Clinical advances in degenerative dementias (*Editorial*) 1–3
- Misra, Arun K. *see* Varma, Vijoy K. *et al* 256–259
- Modai, I. *see* Shiloh, R. *et al* 569–573
- Mohan, Madan S. *see* Adityanjee, M. D. *et al* (C) 485–486
- Molina, Ricard *see* Seoane, Albert *et al* 340–345
- Moloney, E. *see* Smyth, C. *et al* 578–581
- Moncrieff, Joanna. Lithium: evidence reconsidered (*Evidence-based psychiatry*) 113–119
- Montgomery, S. A. *see* Fineberg, N. A. *et al* 280–282
- Moore, R. G. *see* Blackburn, I.-M. 328–334
- Moran, P. *see* Hutchinson, G. *et al* 145–147
- Morgan, H. G. and Stanton, Ruth. Suicide among psychiatric in-patients in a changing clinical scene. Suicidal ideation as a paramount index of short-term risk 561–563
- Morlino, Massimo *et al*. Publication trends of papers on schizophrenia. A 15-year analysis of three general psychiatric journals 452–456
- Morris, M. *see* Lane, A. *et al* 550–555
- Mortensen, P. B. *see* Rossau, C. D. 355–359
- Mortimore, C. *see* Anderson, I. (C) 87
- Mulligan, R. *see* Travis, M. J. *et al* (C) 290–291
- Muris, Peter *et al*. Eye movement desensitisation and reprocessing versus exposure *in vivo*. A single-session crossover study of spider-phobic children 82–86
- Murphy, P. *see* Smyth, C. *et al* 578–581
- Murray, Gordon D. *see* Lang, Fiona H. *et al* 159–164, 165–168
- Murray, R. *see* Van Os, J. *et al* (*Authors' reply*) (C) 289
- Murray, R. M. *see* Hutchinson, G. *et al* 145–147
- Naik, P. C. *see* Lee, A. S. *et al* (*Authors' reply*) (C) 187–188
- Neeleman, Jan *et al*. Suicide by age, ethnic group, coroners' verdicts and country of birth. A three-year survey in inner London 463–467
- Neeleman, Jan and Farrell, Michael. Suicide and substance misuse (*Editorial*) 303–304
- Noble, P. Crime, violence, and schizophrenia (C) 189–190

- North, Clive *et al.* Family functioning and life events in the outcome of adolescent anorexia nervosa 545–549
- Norton, Kingsley *see* Dolan, Bridget *et al* 274–279
- Obholzer, Anton. Reports on psychotherapy commissioned by the National Health Service Executive (*Editorial*) 495–496
- O'Brien, F. *see* Stark, C. *et al* (C) 187
- Odell, S. M. *et al.* Determinants of general practitioner recognition of psychological problems in a multi-ethnic inner-city health district 537–541
- Ohaeri, Jude U. *see* Suleiman, Toyin G. *et al* 364–368
- Ohayon, Maurice M. *et al.* DSM-IV and ICSD-90 insomnia symptoms and sleep dissatisfaction 382–388
- Ohberg, Annakatri *et al.* Driver suicides 468–472
- O'Keane, V. *see* Head, L. (C) 88
- Olhager, E. *see* Dahl, M. L. *et al* (C) 391–392
- O'Neill, J. *see* Smyth, C. *et al* 578–581
- Orija, O. B. *see* Suleiman, Toyin G. *et al* 364–368
- Osola, Karen *see* Selley, Carolyn *et al* 478–482
- Owen, Michael J. & McGuffin, Peter. Genetics and psychiatry (*Editorial*) 201–202
- Özkaynak, S. *see* Karaman, T. *et al* 31–34
- Padmavathi, R. *see* McCreadie, R. G. *et al* 360–363
- Pantelis, C. *see* Speller, J. C. *et al* 564–568
- Parkman, Sue *et al.* Ethnic differences in satisfaction with mental health services among people with psychosis in South London: PRISM Study 4. 260–264
- Parle, Michael *see* Barrowclough, Christine 26–30
- Pashley, David *see* Koffman, Jonathan *et al* 238–241
- Patel, V. *et al.* Common mental disorders in primary care in Harare, Zimbabwe: associations and risk factors 60–64
- Paykel, E. S. *see* Hayhurst, H. *et al* 439–443
- Pelc, I. *et al.* Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study 73–77
- Penttila, Antti *see* Ohberg, Annakatri *et al* 468–472
- Peterson, Edward L. and Breslau, Naomi. Large same-year effects: fact or artefact? (C) 487–488
- Petracca, Gustavo *see* Starkstein, Sergio E. *et al* 47–52
- Petursson, H. *see* Smyth, C. *et al* 578–581
- Peveler, Robert *see* Selley, Carolyn *et al* 478–482
- Phelan, Michael *see* Parkman, Sue *et al* 260–264
- Phookun, Hemen R. *see* Varma, Vijoy K. *et al* 256–259
- Pierides, M. Clozapine monotherapy and ketoacidosis (C) 90–91
- Pilowsky, L. *see* Lucy, J. V. *et al* 346–350
- Pilowsky, L. S. *see* Travis, M. J. *et al* (C) 290–291
- Pinner, G. and Bouman, W. P. Treatment, outcome and predictors of response in elderly depressed in-patients (C) 289
- Pittman, S. *see* Turnbull, G. *et al* (C) 582
- Plomin, Robert *see* Rutter, Michael (*Review Article*) 209–219
- Polge, C. Sigmund: a European database of mental health surveys (C) 91
- Pollitt, Penelope *see* Jorm, Anthony F. *et al* 233–237
- Powell, J. A. & Geddes, J. R. Evidence-based psychiatry (C) 586–587
- Powell, Jane *see* Strang, John *et al* 335–339
- Priest, Robert G. *see* Ohayon, Maurice M. *et al* 382–388
- Proulx, France *et al.* One hundred in-patient suicides 247–250
- Puiggrós, Ana *see* Seoane, Albert *et al* 340–345
- Quinton, Catherine *see* Hepple, Jason 42–46
- Rabins, Peter *see* Howard, Robert (*Editorial*) 406–408
- Radic, Alicja *see* Kirby, Michael *et al* 369–372
- Radwan, M. *see* Shiloh, R. *et al* 569–573
- Ramana, R. *see* Hayhurst, H. *et al* 439–443
- Reischies, Friedel M. and Geiselmann, Bernhard. Age-related cognitive decline and vision impairment affecting the detection of dementia syndrome in old age 449–451
- Reiss, David and Leese, Morven. Psychological debriefing for victims of acute burn trauma (C) 583–584
- Richards, David *see* Strang, John *et al* 335–339
- Rick, J. E. *see* Wall, T. D. *et al* 519–523
- Rifkin, L. *see* Smyth, C. *et al* 578–581
- Ritchie, Karen. Eugeria, longevity and normal ageing (*Editorial*) 501
- Robert, Glenn and Kennedy, Peter. Establishing cost-effectiveness of atypical neuroleptics (*Editorial*) 103–104
- Roberts, A. *see* Fineberg, N. A. *et al* 280–282
- Roberts, D. Transcending barriers between religion and psychiatry (C) 188
- Roberts, Helen *see* Coverdale, John H. *et al* 69–72
- Robertson, Mary M. *et al.* Personality disorder and psychopathology in Tourette's syndrome: a controlled study 283–286
- Rockwell, Enid *see* Caligiuri, Michael P. *et al* 148–153
- Rodenburg, J. J. *et al.* Anxiety and depression in asylum-seekers (C) 394
- Rodgers, Bryan *see* Jorm, Anthony F. *et al* 233–237
- Rollin, Henry. Lunacy in London. Lunacy in Edinburgh (*One hundred years ago*) 91
- Rollin, Henry. Mental disease out-patients (*One hundred years ago*) 587–588
- Rollin, Henry. Royal Lunatic Asylum, Montrose (*One hundred years ago*) 190
- Rollin, Henry. The Lunacy Act, 1890, and its amendments (*One hundred years ago*) 290–291
- Rollin, Henry. The Lunacy Act, 1890, and its amendments (*One hundred years ago*) 488–489
- Rollin, Henry. The Moscow meeting (*One hundred years ago*) 394
- Ronalds, Clare *et al.* Outcome of anxiety and depressive disorders in primary care 427–433
- Rossau, C. D. and Mortensen, P. B. Risk factors for suicide in patients with schizophrenia: nested case-control study 355–359
- Rous, David E. Grey matter correlates of syndromes in schizophrenia (C) 484
- Rutter, Michael and Plomin, Robert. Opportunities for psychiatry from genetic findings (*Review Article*) 209–219
- Ryan, A. Psychopathological syndromes and familial morbid risk of psychosis (C) 289
- Sabe, Liliana *see* Starkstein, Sergio E. *et al* 47–52
- Salib, Emad and Gray, Nicola. Weather conditions and fatal self-harm in North Cheshire 1989 to 1993. 473–477
- Sartorius, N. *see* Craig, T. *et al* (*Authors' reply*) (C) 288
- Sashidharan, S. P. *see* Odell, S. M. *et al* 537–541
- Schmand, Ben *et al.* Subjective memory complaints in the elderly: depressive symptoms and future dementia 373–376

- Schwartz, B. *see* Shiloh, R. *et al* 569–573
- Scott, A. *see* McCracken, C. F. M. *et al* 269–273
- Scott, Christine *et al.* Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care 131–134
- Scott, Jan *see* Scott, Christine *et al* 131–134
- Scully, Paul J. *et al.* Executive (frontal) dysfunction and negative symptoms in schizophrenia: apparent gender differences in 'static' v. 'progressive' profiles 154–158
- Selley, Carolyn *et al.* Post-traumatic stress disorder symptoms and the Clapham rail accident 478–482
- Sengupta, S. & Kar, N. Subjective quality of life and drug treatment for schizophrenia (C) 587
- Seoane, Albert *et al.* Efficacy and safety of two new methods of rapid intravenous detoxification in heroin addicts previously treated without success 340–345
- Sequeira, H. and Halstead, S. Use of seclusion, restraint, and emergency medication (C) 288–289
- Sevcik, P. *see* Hrdlicka, M. (C) 586
- Sham, P. *see* Van Os, J. *et al* (*Authors' reply*) (C) 289
- Shapiro, D. A. *see* Wall, T. D. *et al* 519–523
- Shaw, J. *see* Appleby, L. *et al* (C) 391
- Sheldon, Trevor A. *see* Anderson, Ian *et al* (*Evidence-based psychiatry*) 226–227
- Shiloh, R. *et al.* Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study 569–573
- Siegel, C. *see* Craig, T. *et al* (*Authors' reply*) (C) 288
- Sikdar, Sudip. Evidence-based psychiatry: which evidence to believe? (C) 483–484
- Simkin, Sue *see* Hawton, Keith *et al* 556–560
- Simpson, R. J. Role of GPs in service provision for people with schizophrenia (C) 585
- Simunyu, E. *see* Patel, V. *et al* 60–64
- Singh, Swaran P. Ethnicity in psychiatric epidemiology: need for precision (*Editorial*) 305–308
- Smyth, C. *et al.* Test of Xq26.3–28 linkage in bipolar and unipolar affective disorder in families selected for absence of male to male transmission 578–581
- Sobrepere, Gaudi *see* Seoane, Albert *et al* 340–345
- Solowij, Nadia *see* Hall, Wayne (*Editorial*) 107–108
- Speller, J. C. *et al.* One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol 564–568
- Stanton, Ruth *see* Morgan, H. G. 561–563
- Stark, C. *et al.* Long-term mortality after first psychiatric admission (C) 187
- Starkstein, Sergio E. *et al.* Prospective longitudinal study of depression and anosognosia in Alzheimer's disease 47–52
- Stein, G. *see* Bernadt, M. (C) 484
- Stone, Kit *see* Ronalds, Clare *et al* 427–433
- Strang, John *et al.* Type of hospital setting and treatment outcome with heroin addicts. Results from a randomised trial 335–339
- Suleiman, Toyin G. *et al.* Financial cost of treating out-patients with schizophrenia in Nigeria 364–368
- Surtees, P. G. *see* Odell, S. M. *et al* 537–541
- Susser, Ezra S. *see* Varma, Vijoy K. *et al* 256–259
- Sykes, R. Chronic fatigue syndrome (C) 393
- Szabadi, E. Clozapine-induced hypersalivation (C) 89
- Szmukler, George *see* Bindman, Jonathan *et al* 169–174
- Szmukler, George I. & Bloch, Sidney. Family involvement in the care of people with psychoses. An ethical argument (*Editorial*) 401–405
- Tacchi, Mary Jane *see* Scott, Christine *et al* 131–134
- Takei, N. *see* Hutchinson, G. *et al* 145–147
- Tambs, Kristian *see* Dalgard, Odd Steffen 530–536
- Tannock, Charles *see* Robertson, Mary M. *et al* 283–286
- Tavcar, R. *see* Dernovsek, Z. (C) 393–394
- Taylor, David. Pharmacokinetic interactions involving clozapine (*Review Article*) 109–112
- Taylor, David M. Establishing cost-effectiveness of antipsychotic drugs (C) 486
- Taylor, N. & Bramble, D. Sleep disturbance and Huntington's disease (C) 393
- Terriere, D. *see* Travis, M. J. *et al* (C) 290–291
- Tesón, Alejandra *see* Starkstein, Sergio E. *et al* 47–52
- Thara, R. *see* McCreadie, R. G. *et al* 360–363
- Thompson, Chris *see* Selley, Carolyn *et al* 478–482
- Thornicroft, Graham *see* Becker, Thomas *et al* 15–19
- Thornicroft, Graham *see* Bindman, Jonathan *et al* 169–174
- Thornicroft, Graham *see* McCrone, Paul (*Reading about*) 191–193
- Thornicroft, Graham *see* Parkman, Sue *et al* 260–264
- Todd, C. *see* Patel, V. *et al* 60–64
- Tomenson, Barbara *see* Husain, Nusrat *et al* 434–438
- Tomenson, Barbara *see* Ronalds, Clare *et al* 427–433
- Travis, M. *see* Lucey, J. V. *et al* 346–350
- Travis, M. J. *et al.* Serotonin: 5-HT_{2A} receptor occupancy *in vivo* and response to the new antipsychotics olanzapine and sertindole (C) 290–291
- Treasure, J. Anorexia and the overvalued idea (C) 190
- Tripathi, B. M. *see* Varma, Vijoy K. *et al* 256–259
- Turbott, Sarah H. *see* Coverdale, John H. *et al* 69–72
- Turnbull, G. *et al.* Psychological debriefing for victims of acute burn trauma (C) 582
- Turner, David *see* Becker, Thomas *et al* 15–19
- Turner, M. *see* Lane, A. *et al* 550–555
- Turner, Mark. Malingered (*Editorial*) 409–411
- Turner, Trevor *see* Deahl, Martin (*Editorial*) 6–8
- van der Graaf, Yolanda *see* van der Sande, Rob *et al* 35–41
- van der Sande, Rob *et al.* Intensive in-patient and community intervention versus routine care after attempted suicide. A randomised controlled intervention study 35–41
- van Engeland, Herman *see* van der Sande, Rob *et al* 35–41
- Van Gent, P. P. J. *see* Heeren, T. J. *et al* (*Authors' reply*) (C) 289–290
- van Haften, Hans *see* Muris, Peter *et al* 82–86
- Van Os, J. *et al.* Psychopathological syndromes and familial morbid risk of psychosis (*Authors' reply*) (C) 289
- van Rooijen, Liesbeth *see* van der Sande, Rob *et al* 35–41
- Varma, Vijoy K. *et al.* Effects of level of socio-economic development on course of non-affective psychosis 256–259
- Vearnals, S. *see* Hayhurst, H. *et al* 439–443
- Verbanck, P. *see* Pelc, I. *et al* 73–77

Volavka, Jan *et al.* History of violent behaviour and schizophrenia in different cultures. Analyses based on the WHO study on Determinants of Outcome of Severe Mental Disorders 9–14

Vollmer-Conna, Ute *et al.* Cognitive deficits in patients suffering from chronic fatigue syndrome, acute infective illness or depression 377–381

Waddington, John L. *see* Scully, Paul J. *et al* 154–158

Wainwright, N. W. J. *see* Odell, S. M. *et al* 537–541

Wakefield, Denis *see* Vollmer-Conna, Ute *et al* 377–381

Walker, Z. *see* Allen, R. L. *et al* 486–487

Wall, T. D. *et al.* Minor psychiatric disorder in NHS trust staff: occupational and gender differences 519–523

Warner, James P. *see* Gledhill, Julia A. *et al* 228–232

Warren, Fiona *see* Dolan, Bridget *et al* 274–279

Webb, Sarah *see* Ronalds, Clare *et al* 427–433

Weinberger, D. R. *see* Knable, M. B. *et al* 574–577

Weizman, A. *see* Shiloh, R. *et al* 569–573

Wessely, Simon *see* Neeleman, Jan *et al* 463–467

Wessely, Simon. Chronic fatigue syndrome (*Reading about*) 92–93

West, M. A. *see* Wall, T. D. *et al* 519–523

Westbrook, Reginald F. *see* Vollmer-Conna, Ute *et al* 377–381

Wig, N. N. *see* Varma, Vijoy K. *et al* 256–259

Wikler, D. *see* Biver, F. *et al* 444–448

Williams, K. E. *see* McCracken, C. F. M. *et al* 269–273

Wilson, K. *see* McCracken, C. F. M. *et al* 269–273

Winston, M. *see* Patel, V. *et al* 60–64

Wright, Steve *see* Bindman, Jonathan *et al* 169–174

Wyatt, Richard J. *see* Fenton, Wayne S. *et al* 265–268

Yaltkaya, K. *see* Karaman, T. *et al* 31–34

Yorston, G. Depressive delusions and the general election (C) 585

Zemishlany, Z. *see* Shiloh, R. *et al* 569–573

PART III. BOOK REVIEWS

Baltes, Margaret M. The many faces of dependency in old age (Vincent Kirchner) 298

Beard, Jonathan C. Illicit drug use. Acute and chronic pharmacological intervention (Susan M. Ruben) 97

Blackburn, Ivy-Marie & Twaddle, Vivien. Cognitive therapy in action: a practitioner's casebook (Gillian Butler) 295–296

Breggin, P. R. & Stern, E. M. Psychosocial approaches to deeply disturbed persons (Frank Holloway) 493

Bright, Ruth. Grief and powerlessness: helping people regain control of their lives (Graeme Feggetter) 298

Bryan, K. and Maxim, J. (eds). Communication disability and the psychiatry of old age (Brian A. Lawlor) 94–95

Busfield, Joan. Men, women and madness: understanding gender and mental disorder (Rosalind Ramsay) 194

Clark, D. H. The story of a mental hospital: Fulbourn 1858 to 1983 (Douglas Bennett) 293–294

Cohen, Robert M. Patient management problems for the MRCPsych (Ashok G. Patel) 593

Committee on Cultural Psychiatry, Group for the Advancement of Psychiatry Report No. 141. Alcoholism in the United States: racial and ethnic considerations (Bruce Ritson) 595

Conacher, Geoffrey Neil. Management of the mentally disordered offender in prisons (Will Walker) 296

Cordess, C. & Cox, M. C. (eds). Forensic psychotherapy. Crime, psychodynamics and the offender patient (Volumes 1 and 2) (Gisli H. Gudjonsson) 100–101

Crawford, Isaiah, Crawford & Fishman, Baruch (eds). Psychosocial interventions in HIV disease: a stage-focused and culture-specific approach (Paul Flowers) 299

Esiri, Margaret M. and Morris, James H. (eds). The neuropathology of dementia (John O'Brien) 590

Friedhoff, Arnold J. & Amin, Farooq (eds). Plasma homovanillic acid in

schizophrenia: implications for presynaptic dopamine dysfunction (Louise Golightly) 591

Gelder, M., Gath, D., Mayou, R. & Cowen, P. (eds). Oxford textbook of psychiatry (3rd edition) (Michael King) 96

Gersie, Alida (ed.). Dramatic approaches to brief therapy (Jim Wilson) 592

Gill, Eliana. Treating abused adolescents (Nick Goddard) 97

Goldsmith, Malcolm. Hearing the voice of people with dementia: opportunities and obstacles (David Jolley) 98–99

Goodman, Neville W. and Edwards, Martin B. Medical writing: a prescription for clarity (2nd edn) (Andrew Morris) 490–491

Green, John & McCreaner, Alana. Counselling in HIV infection and AIDS (2nd edn) (Bernard Ratigan) 491

Grubin, Don. Fitness to plead in England and Wales (Maudsley Monograph 38) (A. M. P. Kellam) 101

Grubrich-Simitis, I. Back to Freud's text: making silent documents speak (Jonathan Sklar) 592–593

Guthrie, Elspeth and Creed, Francis (eds). Seminars in liaison psychiatry (George Masterton) 96–97

Haber, Russell. Dimensions of psychotherapy supervision – maps and means (Julian M. Stern) 95–96

Harris, John, Allen, David, Cornick, Marion, Jefferson, Alan & Mills, Richard. Physical interventions: a policy framework (T. P. Berney) 493

Haslam, M. T. Clifton Hospital – an era (Douglas Bennett) 293–294

Heimberg, Richard G., Liebowitz, Michael R., Hope, Debra A. & Schneier, Franklin R. (eds). Social phobia: diagnosis, assessment and treatment (Dougal Mackay) 99

Hersen, Michael & Van Hasselt, Vincent B. (eds). Psychological treatment of older adults: an introductory text (David Ames) 99–100

Hollin, Clive R. (ed.). Working with offenders: psychological practice in offender rehabilitation (Deborah Brooke) 100

Hollin, Clive R. & Howells, Kevin (eds). Clinical approaches to working with young offenders (Carol Sheldrick) 96

- Holmes, C. & Howard, R. (eds). *Advances in old age psychiatry: chromosomes to community care* (D. Jolley) 591–592
- Hope, Debra A. (ed.). *Nebraska symposium on motivation volume 43: perspectives on anxiety, panic, and fear* (Isaac Marks) 490
- Jablensky, A. (ed.). *Epidemiological psychiatry* (Terry Brugha) 95
- Jamison, Kay Redfield. *Touched with fire: manic depressive illness and the artistic temperament* (Anthony W. Clare) 395
- Johnstone, Gerry. *Medical concepts and penal policy* (David Tidmarsh) 95
- Kaplan, Harold I. and Sadock, Benjamin J. *Pocket handbook of primary care psychiatry* (Scott Welch) 593
- Kaslow, F. W. (ed.). *Handbook of relational diagnosis and dysfunctional family patterns* (Justin Schlicht) 197–198
- Kiesler, Donald. *Contemporary interpersonal theory and research: personality, psychopathology and psychotherapy* (Phil Mollon) 295
- Klonoff, Elizabeth A. & Landrine, Hope. *Preventing misdiagnosis of women. A guide to physical disorders that have psychiatric symptoms* (Fiona Subotsky) 491–492
- Laufer, Moses (ed.). *The suicidal adolescent* (Queenie Harris) 492
- Lawlor, Brian A. (ed.). *Behavioural complications in Alzheimer's disease* (David N. Anderson) 100
- Lomax, Eric. *The railway man* (O. Daly) 294
- Lyman, Robert D. & Campbell, Nancy R. *Treating children and adolescents in residential and inpatient settings* (William L. I. Parry-Jones) 197
- McLynn, Frank. *Carl Gustav Jung: a biography* (Catherine Crowther) 396–397
- Meyers, Robert J. and Smith, Jane Ellen. *Clinical guide to alcohol treatment: the community reinforcement approach* (Malcolm Bruce) 296–297
- Mollon, Phil. *Multiple selves, multiple voices: working with trauma, violation and dissociation* (Harold Merskey) 297
- Morgan, Steve. *Helping relationships in mental illness* (Peter H. Dick) 196–197
- Nutt, D. J. & Mendelson, W. B. (eds). *Hypnotics and anxiolytics. Baillière's international practice and research series, vol. 1, no. 3* (James Lindesay) 94
- Pallone, Nathaniel J. & Hennessy, James. *Tinder-box criminal aggression* (Alec Buchanan) 589
- Palmer, Stephen & Dryden, Windy (eds). *Stress management and counselling: theory, practice, research and methodology* (Graeme McGrath) 594–595
- Paris, Joel. *Social factors in the personality disorders. A biopsychosocial approach to etiology and treatment* (Mairéad Dolan) 194
- Phillips, Rena & McWilliam, Emma (eds). *After adoption: working with adoptive families* (Stephen Isaacs) 197
- Philo, G. (ed.). *Media and mental distress* (Raj Persaud) 194–195
- Prohovnik, I., Wade, J., Knezevic, S., Tatemichi, T. and Erkinjuntti, T. (eds). *Vascular dementia – current concepts* (Colm Cooney) 594
- Rapee, Ronald M. (ed.). *Current controversies in the anxiety disorders* (Peter Hayward) 296
- Rommelspacher, H. & Schuckit, M. A. (eds). *Clinical psychiatry, international practice and research – drugs of abuse* (Emily Finch) 491
- Russell, David. *Scenes from Bedlam: a history of caring for the mentally disordered at Bethlem Royal Hospital and the Maudsley* (Kevin Gournay) 294–295
- Saradjian, J. *Women who sexually abuse children – from research to clinical practice* (Estela V. Welldon) 492–493
- Shirar, Lynda. *Dissociative children: bridging the inner and outer worlds* (Dora Black) 97–98
- Shorter, Edward. *A history of psychiatry: from the era of the asylum to the age of Prozac* (Allan Beveridge) 397
- Sperry, Len. *Corporate therapy and consulting* (Anton Obholzer) 395–396
- Sperry, Len, Brice, Peter L., Howard, Kenneth I. & Grisson, Grant R. *Treatment outcomes in psychotherapy and psychiatric interventions* (Mental health practice under managed care, Volume 6) (R. H. Cawley) 195
- Stadter, M. *Object relations brief therapy – the therapeutic relationship in short-term work* (Geoff Fisk) 593–594
- Stahler, G. J. & Stimmel, B. (eds). *The effectiveness of social interventions for homeless substance abusers* (Joe Herzberg) 297–298
- Sturmey, Peter. *Functional analysis in clinical psychology* (Ailsa Russell) 98
- Towl, G. T. & Crighton, D. A. *The handbook of psychology for forensic practitioners* (Tim McInerney) 595–596
- Tseng, Wen-Shing & Streitzer, Jon (eds). *Culture and psychopathology – a guide to clinical assessment* (David B. Mumford) 591
- Tsiantis, John, Sandler, Anne-Marie, Anastasopoulos, Dimitris & Martindale, Brian (eds). *Countertransference in psychoanalytic psychotherapy with children and adolescents* (Adrian Sutton) 298–299
- Valentine, R. *Asylum, hospital, haven – a history of Horton Hospital* (Douglas Bennett) 293–294
- Varma, Ved (ed.). *The inner life of children with special needs* (Karen Bretherton) 94
- Varma, Ved (ed.). *Violence in children and adolescents* (Nicky von Fraunhofer) 397–398
- Violanti, John M. *Police suicide: epidemic in blue* (Gwen Adshead) 196
- Wells, Kenneth, Sturm, Roland, Sherbourne, Cathy and Meredith, Lisa. *Caring for depression* (Jan Scott) 195–196
- Wilmot, Stephen. *The ethics of community care* (Martin P. Deahl) 590–591
- Wright, David and Digby, Anne (eds). *From idiocy to mental deficiency* (Ian Hall) 196